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The last two decades have seen the zoonotic emergence of three highly pathogenic 
coronaviruses (CoVs): MERS-, SARS- and SARS-CoV-2. Their epidemic and pandemic 
spread, respectively, underlines the importance of monitoring emerging CoVs and of 
developing a deeper understanding of the molecular mechanisms that contribute to their 
emergence and pathogenicity. CoV are highly diverse in their animal reservoirs, yet how this 
diversity translates to phenotypical traits that may account for the zoonotic and pandemic 
potential of these viruses remains elusive.  
In the first part, several generated clinical Middle East respiratory syndrome coronavirus 
(MERS-CoV) isolates pertaining to different phylogenetic clades were analyzed for their in-
vitro and ex-vivo infection phenotypes. Importantly, the isolate diversity used here reflects 
phylogenetic lineages sampled before and after the year 2015, when a novel phylogenetic 
lineage emerged by a recombination event (MERS-CoV lineage 5) and superseded other, 
hitherto co-circulating viral lineages from circulation, as well as causing large nosocomial 
outbreaks in Saudi Arabia and South Korea. The present studies demonstrate that MERS-CoV 
recombinant lineage 5 isolates have increased replicative capacity in the human lung, in 
correlation with increased interferon resilience and signaling antagonism. These phenotypic 
differences might explain the dominance of lineage 5 on the Arabian Peninsula and suggests 
an increased pandemic potential of the currently circulating MERS-CoV lineage 5.  
The second part comprises a phenotypical comparison of severe acute respiratory syndrome 
coronavirus (SARS-CoV) and SARS-CoV-2, focusing on potential differences in their capacity 
to antagonize the innate immune response. Both viruses share a completely homologous 
repertoire of open reading frames (ORFs) and pertain to the same phylogenetic clade of SARS-
related CoV, yet display differences in their transmission efficiencies and pathogenic traits. 
The data presented here show that SARS-CoV-2 is more sensitive to the antiviral activity of 
interferons and that SARS-CoV-2 is less efficient in antagonizing cytokine induction and 
interferon signaling. SARS-CoV-2 protein 6 expressed in the context of a fully replicating 
SARS-CoV backbone had reduced functionality in suppressing interferon signaling induction, 
suggesting that the overall reduced antagonism of SARS-CoV-2 might therefore by a function 







Drei hochpathogene Coronaviren (CoV) sind in den letzten zwei Jahrzehnten auf den 
Menschen übergegangen: MERS-, SARS- und SARS-CoV-2. Insbesondere die Ausbreitung 
des SARS-CoV-2 zeigt auf, wie wichtig die Überwachung neu auftretender CoV ist. Die 
aktuelle Pandemie demonstriert auch welche Relevanz es für unser Gesundheitswesen hat 
ein tiefergehendes Verständnis für jene Faktoren zu entwickeln, die das Infektionsrisiko und 
die Pathogenität solcher Viren beeinflussen. Die Diversität von CoV ist in ihren tierischen 
Reservoiren groß, doch wie sich diese Vielfalt auf phänotypische Merkmale auswirkt, 
besonders auf solche, die das zoonotische und pandemische Potenzial dieser Viren 
beeinflussen könnten, ist nach wie vor unklar. 
Im ersten Teil der Dissertation wurden in verschiedenen in-vitro- und ex-vivo- Modellen 
mehrere klinische MERS-CoV-Isolate phänotypisch analysiert. Es konnte gezeigt werden, 
dass die hierfür isolierten Viren repräsentativ für drei unterschiedliche phylogenetischen 
Kladen sind, und mit MERS-CoV Linie 5 jene Klade beinhalten, die in oder vor 2014 durch ein 
Rekombinationsereignis entstanden ist, und nachträglich alle bis dato zirkulierenden 
Viruslinien verdrängt hat. Die vorliegende Studie zeigt, dass Virusisolate der rekombinanten 
MERS-CoV-Linie 5 eine erhöhte Replikationskapazität in der menschlichen Lunge haben, die 
mit einer erhöhten Interferon-Resilienz und einer effektiveren Unterdrückung der Interferon-
spezifischen Signaltransduktionskaskade korrelierend. Diese phänotypischen Unterschiede 
könnten die mögliche Dominanz der Linie 5 auf der Arabischen Halbinsel erklären und 
implizieren, dass die aktuell zirkulierende MERS-CoV Linie 5 ein erhöhtes zoonotisches und 
pandemisches Risiko für den Menschen darstellt. 
Der zweite Teil der Dissertation umfasst einen phänotypischen Vergleich von SARS- und 
SARS-CoV-2 mit besonderem Fokus auf die virale Interaktion mit der angeborenen Immunität 
in Wirtszellen. Beide Viren zeigen ein vollständig homologes Repertoire von offenen 
Leserahmen (open reading frames, ORFs) und gehören der gleichen phylogenetischen Art, 
den SARS-verwandten CoV an. Die Viren unterscheiden sich jedoch deutlich in ihrer 
Übertragungseffizienz und in ihrer Pathogenese im Menschen. In dieser Arbeit konnte gezeigt 
werden, dass SARS-CoV-2 weniger resilient gegenüber der antiviralen Wirkung von Interferon 
ist. Im Vergleich zu SARS-CoV kann SARS-CoV-2 die Zytokininduktion und Interferon-
Signalübertragung weniger effizient unterdrücken. Mittels reverser Genetik konnte gezeigt 
werden, dass das SARS-CoV-2 Protein 6 im Kontext eines vollständig replizierenden SARS-
CoV eine geringere Effizienz als SARS-CoV Protein 6 hat, die Interferon-
Signaltransduktionskaskade zu blockieren.  
3 
 
1 – General Introduction 
 
Coronaviruses (CoV; order Nidovirales, family Coronaviridae) are positive sense, single 
stranded RNA viruses of exceptional genomic complexity and the capacity to infect a broad 
range of invertebrate and vertebrate hosts [1-3]. Human pathogenic CoVs (HCoVs) have first 
been notified in the late 1960s and have since then been observed as a frequent, yet mild 
cause of “common cold”-like, acute respiratory syndromes in humans [4, 5].  
The global spread of three highly pathogenic CoVs within the last two centuries (SARS-CoV 
in 2002, MERS-CoV in 2012 and SARS-CoV-2 in 2019 [6-8]) has shifted that perception and 
demonstrated the importance of monitoring newly emerging CoVs and to develop a deeper 
mechanistic understanding of their biology and evolution (Figure 1). 
 
Figure 1: CoVs known to infect humans (HCoV) and their time point of emergence. CoVs were 
initially discovered in poultry (Infectious Bronchitis Virus, IBV) in 1937 [9]. IBV and other animal CoVs 
are important livestock pathogens, but not focused on here. The low pathogenic HCoV-229E and OC43 
have been known to cause seasonal “common cold” respiratory syndromes in humans for over 50 years 
[4, 5]. The SARS pandemic in 2003 intensified CoV surveillance and led to the discovery of two more 
HCoVs, HCoV-NL63 and HKU1 [10, 11]. Seasonal HCoV are estimated to cause around 15% of acute 
respiratory tract infections in humans [12-14]. References for SARS-, MERS- and SARS-CoV-2 
emergence are displayed in the main text. * refers to the date of writing, i.e. 20.07.2020.; case and 

















































1.1 – CoV genome complexity 
 
With genomes sizes of 12 to 41 kb (averaging 26 to 31 kb) Nidovirales constitute the largest 
known RNA based lifeforms on earth [15]. A prevailing dogma, proposed by Manfred Eigen 
(†2019) in his famous 1971 paper, states a positive correlation between genome complexity 
and replication fidelity [16]. The large Nidovirales RNA genomes appear to be a remarkable 
exception to that rule, since other RNA virus families (averaging 2 to 12 kb genomes) show 
average replication error rates 10,000 to 100,000 times higher than DNA replication error rates 
[17-20], trapping RNA viruses at the lower end of genome complexity. Fundamentally, RNA 
polymerases lack the ability to correct for errors during replication (proofreading) and have 
evolved a replication fidelity low enough to allow for the generation of a maximally diverse 
“cloud” of variants in the population (referred to as the viral quasispecies) [21-23]. The 
quasispecies provides the basis for natural selection to work upon and contributes a major 
explanation for the huge adaptability observed in RNA virus species [24, 25]. However, artificial 
increases in the mutation rate of RNA viruses pushes species into a state of intolerable 
accumulation of mutations, often referred to as “error catastrophe” [26-29].  
Nidovirales evolution has uniquely overcome this trap by acquisition of a complex replication 
machinery of which one protein subunit (non-structural protein 14, nsp14) encodes for a 
domain with exonuclease activity (ExoN), similar in function to proofreading domains of DNA 
polymerases [30-34]. The emergence of RNA proofreading activity is believed to have 
facilitated genome expansion in Nidovirales and is in line with Eigen´s theory that predicts 
inverse correlation of mutation rate and genome complexity (reviewed in [2]). In a Darwinian 
sense, increased genomic complexity provides a broader basis for natural selection to work 





1.2 – CoV diversity and bat ancestry 
 
Nidovirales are considered the second most diverse order of positive-sense RNA viruses, after 
the Picornaviridae, comprising 109 formally recognized species, 46 of which pertain to the 
family Coronaviridae [35]. The remaining species of Nidovirales belong to the family of 
Arteriviridae and Roniviridae [35]. Phylogenetic inferences suggest a further division of 
Coronaviridae into four genera, the Alpha-, Beta-, Gamma-, and Deltacoronavirus (Figure 2B), 
each of which contains several sub-clades. Interestingly, the split of alpha-/betacoronaviruses 
and gamma-/deltacoroanviruses coincides with a split in host tropism, with members of the 
former group infecting primarily mammals, and the latter infecting primarily (but not exclusively) 
birds [36]. Five of the seven CoVs known to infect humans (including the three highly 
pathogenic strains, SARS-CoV, SARS-CoV-2, MERS-CoV; as well as HCoV-OC43 and HCoV-
HKU1; Figure 1), pertain to the genus Betacoronavirus and two belong to the 
alphacoronaviruses (HCoV-229E and HCoV-NL63) (Figure 2A).  
There is strong evidence for a zoonotic origin of all human CoVs, i.e. that they originated in 
animal reservoirs (reviewed in [37]). Phylogenies constructed from the increasingly complex 
data of metagenomics strongly suggest that ancestral CoVs might have emerged in bat 
species (reviewed in [38]). In fact, all of the CoVs known to infect humans have bat ancestors, 
but frequently involve intermediate hosts [39-49], with the exception of HCoV-OC43 and HKU1 




Figure 2: CoV phylogeny and animal origin, with focus on HCoV. A) Displayed is a maximum-
likelihood phylogeny of selected Alpha- (HCoV-229E and -NL63) and Betacoronavirus (all other names) 
species. CoVs known to infect humans (red names, severe infection in humans; orange names, mild 
infection), cluster within clades of species identified in bats (black names), arguing for close evolutionary 
distance between them (not shown for alphacoronaviruses). The tree was calculated with the 
Shimodaira–Hasegawa (SH) method and 1,000 replicates (the higher the %-value (SH-ratio), the higher 
the support of a node; top left panel) and was adapted from [52] B) Bayesian inference phylogeny of 
selected members of the Coronaviridae family, with Cavally virus as an outlier species. The tree displays 
the split into the four genera Alpha-, Beta-, Gamma-, and Deltacoronavirus and was adapted from [38]. 
More details on the construction of phylogenies in A) and B) are provided in the respective references. 
C) Schematic display of emergence of HCoVs, with color code as above. Left panel shows HCoVs that 












1.3 – Highly pathogenic CoVs: MERS-,  
SARS- and SARS-CoV-2 
 
Middle East respiratory syndrome coronavirus (MERS-CoV), a 2c betacoronavirus, is the 
causative agent of a novel form of severe viral pneumonia in humans [7]. MERS-CoV emerged 
in 2012 and the majority of currently more than 2,494 notified cases, including 858 deaths, 
occurred on the Arabian Peninsula. Travel-associated cases were diagnosed in 27 countries 
and sparked secondary case clusters in some. The largest MERS-CoV outbreak outside the 
Arabian Peninsula occurred in South Korea in 2015, involving 186 cases and 36 deaths (WHO, 
June 2020). MERS-CoV is acquired as a zoonotic infection from dromedary camels [53-56] 
and likely originated in bats [42, 57]. Spillover from dromedaries to humans can lead to local 
outbreaks with limited human-to-human transmission [58, 59]. Healthcare facilities can 
experience protracted outbreaks with severe infections in co-morbid patients [60]. Behavioral 
factors like family patient care may accelerate outbreaks [61-63].  
SARS-CoV is a group 2b betacoronavirus that emerged in 2002 in the Guangdong Province 
of China and was identified as the causative agent of the Severe Acute Respiratory Syndrome 
(SARS) [6]. The transmission dynamics of SARS-CoV are relatively low and despite having 
spread to 29 countries and infecting more than 8000 patients with 774 deaths the SARS 
pandemic was halted by public health interventions in 2003 [64]. As described in chapter 1.2, 
SARS-related CoVs originate in bats, but in the case of the 2002 SARS-CoV, palm civets and 
raccoon dogs have been implicated to act as intermediate hosts [65].   
SARS-CoV-2 was identified as the etiological agent of a novel viral pneumonia, called COVID-
19 in late 2019 [8]. Since then, it has rapidly shifted from initial local case clusters in the Hubei 
province in China to a pandemic with over 12,000,000 cases and over 600,000 deaths (WHO, 
July 2020). The novel virus pertains to the same species as the etiological agent of the SARS 
pandemic in 2002/3 [52]. Therefore, SARS-CoV-2 and SARS-CoV share striking similarities in 
their genome architecture [66], in receptor and host protease usage [67] and in emergence 
from an initial zoonotic acquisition with bat ancestry [46]. However, SARS-CoV-2 seems to be 
distinct from SARS-CoV in its clinical and epidemiological presentation, with lower 





1.4 – CoV genome organization and  
protein expression strategy 
 
CoV genomes contain several higher order RNA structures. The 5´ and 3´ ends of the viral 
genome comprise untranslated regions (UTR) required for genome replication and 
transcription. UTRs may vary in sequence length between different CoV species, but share a 
conserved core area in the 5´UTR, which comprises the leader TRS (transcription regulatory 
sequence, TRS) that interacts with body TRS located upstream of structural and accessory 
genes during their transcription (see below) [69, 70] (Figure 3).  
Two thirds of the genome comprises ORF1 that is translated directly from the capped and 
polyadenylated genomic RNA as two large polyproteins (pp1a and pp1ab) by means of an 
RNA pseudoknot-mediated -1 ribosomal frameshift [71]. The polyproteins are proteolytically 
processed by the viral proteases PLpro (Papain-like protease, in nsp3) and 3CLpro 
(chymotrypsin-like protease 3, in nsp5) to yield 16 (in some species only 15) nsps [72, 73]. 
While mutagenesis studies could demonstrate an essential function of the nsps for replication, 
their precise individual function is still under debate, particularly because most exhibit multi-
functionality. Yet in principle, the nsps encode for the components of the multi-structural 
replication transcription complex (RTC) that governs the production of viral RNAs, for proteins 
that rearrange cellular membranes to create a double-membrane vesicle environment 
proposed to host CoV replication, or for proteins that interfere with the antiviral host response 
(see below) [74-80].  
The last third of the CoV genome encodes for structural and accessory proteins that are 
translated from subgenomic mRNAs (sgmRNAs; chapter 1.5). Structural proteins form the 
virus particle and are common to all CoVs. These comprise the spike protein, which mediates 
entry into and attachment to host cells by binding to host cell proteins (called receptors), the 
envelope (E) and membrane (M) protein, as well as the genome-encapsidating nucleocapsid 
(N) protein [67, 81, 82]. Accessory proteins comprise a range of proteins that may vary in 
number between different CoV species. These are non-essential for virus replication (therefore 
called accessory), but implicated in in vivo pathogenesis and/or suppression of the antiviral 





Figure 3: CoV genome organization and protein expression strategy. Exemplified for MERS-CoV. 
Upper panel: MERS-CoV genome and its 11 open reading frames (ORFs): ORF1 (split into ORF1a and 
ORF1b, which express proteins required for replication and transcription), the structural ORFs 
(expressing spike-, envelope- (E), membrane- (M), nucleocapsid- (N) protein), and accessory ORFs 
(expressing p4a, p4b, p5 and p8). Replicase and structural ORFs are present in all CoVs; the number 
of accessory ORFs varies between species. SARS- and SARS-CoV-2 encode for nine accessory ORFs 
(not shown here). Important regulatory RNA elements are shown in the top panel (left to right): cap 
structure, 5´ UTR (for untranslated region), Leader TRS (for Transcription Regulatory Sequence; see 
chapter below), RNA stem-loop causing a -1 ribosomal frameshift to govern ORF1b expression, nine 
body TRS, 3´UTR and the poly(A)tail. Bottom panel: viral polyprotein expression and maturation. Both 
polyproteins are translated from the viral genome, 1ab via a -1 ribosomal frameshift. The numbers 
indicate respective non-structural proteins (nsps). Triangles indicate cleavage sites in the viral 
polyprotein, with matching color code (PLpro sites in dark; 3CLpro sites in white). Functional protein 
domains that are mentioned in this or following sections of the main text are highlighted. PLpro, Papain-
like protease (nsp3); 3CLpro, chymotrypsin-like protease 3 (nsp5); RdRp, RNA-dependent RNA 
polymerase (nsp12); ExoN, 3′-to-5′exoribonuclease (nsp14); N7-MTase, N7-guanine methyl transferase 
(nsp14); endoU, uridylate-specific endoribonuclease (nsp15); 2′-O-MTase, 2′-O-methyl transferase 
(nsp16). Structural and accessory proteins expression follows translation from sgmRNAs, produced by 
discontinuous transcription (see chapter 1.5).  
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1.5 – CoV life cycle and replication strategy 
 
CoV follow a unique replication and transcription strategy, summarized in Figure 4 and 
reviewed in [87].   
Attachment to host cells is mediated by protein-protein interactions between viral spike and 
cellular receptor proteins, dipeptidylpeptidase 4 (DPP4) in MERS- [81] and angiotensin-
converting enzyme 2 (ACE2) in SARS- and SARS-CoV-2 infection [67, 88]. Attachment may 
be augmented by additional binding to cellular sugar residues, sialic acids in the case of 
MERS-CoV [89] or additional cellular proteins, DC-SIGN in SARS-CoV infection, respectively 
[90]. Receptor recognition triggers conformational changes in the spike protein that drive the 
fusion of viral envelope and cellular membranes [91]. In the classical pathway, fusion occurs 
inside cellular endosomes following receptor-mediated endocytosis of receptor bound viral 
particles [91]. An alternative pathway that allows for fusion directly at the plasma membrane in 
dependence of additional proteolytic spike protein procession by cellular proteases could be 
demonstrated for all three highly pathogenic CoVs (MERS-, SARS- and SARS-CoV-2) [92-
100]. Following receptor-mediated entry, the viral genome is uncoated and released into the 
host cytoplasm. As detailed above, viral nsps are translated directly from the viral genome. 
Following their expression and proteolytic procession, the nsps rearrange host membranes to 
form double-membrane vesicles, the putative platform of virus replication and transcription [74, 
101, 102]. Here, the replication-transcription complex replicates the viral genome and 
transcribes structural and accessory protein encoding sgmRNAs, detailed below. Nascent 
virus particles are formed by interaction of expressed structural proteins and nucleocapsid-
mediated interaction of replicated genomes at ER-Golgi intermediate compartments (ERGIC) 
and follow export and maturation over the trans-Golgi route [82, 103-106] (Figure 4A).  
Genome replication requires the transcription of full-length (genomic) negative-strand (minus-
strand) RNA, which serves as the template for the production of full-length (genomic) positive-
strand (plus-strand) RNA (Figure 4B). The production of sgmRNAs is governed by a process 
called discontinuous transcription and is fundamentally different to genome replication 
(reviewed in [72, 107]). In essence, the viral replication-transcription complex uses genomic 
positive-strand RNA as template and starts the transcription of negative-strand RNA from the 
3´end of the viral genome. When a body TRS, located 5´ of each structural or accessory gene, 
is encountered, negative-strand transcription either continuous to the next TRS, or the 
replication-transcription complex dissociates to transfer the nascent RNA to the leader TRS at 
the 5´ end of the genome, guided by sequence complementarity of body TRS and leader TRS. 
Transcription of negative-strand RNA continuous over the leader until the 5´end of the genome 
11 
 
is reached. Fused leader-body negative-strand RNAs are transcribed to yield positive-strand 
sgmRNAs, the template for viral protein translation (Figure 4B). Discontinuous transcription is 
a hallmark of the Nidovirales family and the resulting production of a set of 3´ coterminal, or 
“nested” sgmRNAs has coined their name (“nido” is the Latin word for “nest”).  Of note, the 
process also allows for a passive control over the abundance of transcripts, as the ORFs 
towards the 3´end of the genome will be transcribed more frequently. 
 







b) minus-strand sgmRNA synthesis
c) nascent minus-strand sgmRNA 
transferred to leader TRS 





Figure 4: CoV life cycle and replication strategy. A) CoV life cycle. After receptor-mediated entry (1), 
the viral RNA is uncoated in the cytoplasm (2). Viral nsps are translated and proteolytically processed 
directly from the viral genome (3). The nsps rearrange cellular membranes to form double-membrane 
vesicles (DMV) (4) which host the viral replication and sgmRNA transcription (5) and detailed in B). 
sgmRNAs are translated to structural proteins (6) that are assembled into the nucleocapsid and viral 
envelope at the ER–Golgi intermediate compartment (ERGIC) (7), followed by Golgi-mediated release 
(8) of the nascent virion from the infected cell (9) B) CoV Replication strategy. a) genome replication, 
full-length negative-strand (- sense) RNA copies of the genome are produced that serve as templates 
for full-length positive-strand (+ sense) RNA genomes. b-d) discontinuous transcription of structural and 
accessory proteins sgmRNAs. b) sg minus-strand RNAs are transcribed starting from the 3´end of the 
genome until a body TRS is encountered. Transcription either continues to the next TRS or c) the 
nascent strand is transferred to the leader TRS. Transcription continues over the leader TRS sequence. 
d) The produced leader-fused negative-strand sgmRMAs are transcribed into positive strand sgmRNAs, 
the template for translation.   
 
1.6 – Interaction of CoVs with the innate immune system 
The complex interactions between viruses and their hosts has driven metazoan evolution to 
develop sophisticated immune systems to fight virus infections. In turn, in an “evolutionary 
arms race,” viruses have evolved innumerable strategies to overcome these systems [108-
111].  
Vertebrate immune systems comprises two subtypes that are acting and interacting in 
complementing ways to fight  infections: adaptive (or antigen-specific) immunity and innate (or 
antigen-non-specific) immunity, reviewed in [112]. In essence, adaptive immunity comprises 
“tailor-made,” specific responses to a specific antigen and primarily acts via subsets of cells, 
the leukocytes, including antibody producing B-cells and cytotoxic (cell killing) T-cells. The 
adaptive immune response is launched in a time-delayed fashion, as the activation and 
maturation of these cells requires previous antigen recognition and processing [113].  
In contrast, components of innate immunity are present in all cell types and can immediately 
engage in a rather unspecific response by a mechanism called “pattern recognition”. 
Fundamentally, distinct “non-self” structural motives, called pathogen associated molecular 
patterns (PAMPs), are detected by a number of sentinel proteins, or pattern recognition 
receptors (PRRs) [114]. The detection of PAMPs activates a signaling cascade leading to 
downstream activation and nuclear translocation of transcription factors, in the case of viral 
infections most notably interferon (IFN) regulator factors (IRF3 and IRF7) and nuclear factor 
kB (NF-kB) [114]. In CoV infection, the innate immune response is primarily launched by the 
cellular helicase melanoma-differentiation antigen 5 (MDA5) that binds to double-stranded 
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RNA replication intermediates, produced during negative-strand synthesis [115]. The 
activation of NF-kB and IRFs exemplifies two complementary antiviral strategies: NF-kB 
induces the transcription of chemokines that primarily act in the recruitment and activation of 
leukocytes, while IRFs induce the transcription of type I and type III IFNs (IFN-I, comprising 
IFNα and IFNβ subtypes and IFN-III, respectively, comprising IFNλ subtypes). In a paracrine 
manner, secreted IFNs induce IFN-stimulated genes (ISGs) by binding to cellular IFN 
receptors and activating the Janus kinase/ signal transducers and activators of transcription 
(JAK/STAT) signaling cascade (also called IFN signaling cascade) [116]. ISGs encode for over 
300 proteins with antiviral properties that can be broadly categorized as proteins immediately 
impeding virus replication (e.g. Mx1, ISG56, proteins of the IFIT and IFITM family), sentinel 
proteins (e.g. TLRs, the RIG-I-like receptor family, including MDA5), transcription factors (e.g. 
the STAT family or IRFs) and proteins functioning in immune regulatory signaling [117, 118]. 
CoVs are highly sensitive to the antiviral action of IFN signaling, in vitro and in non-human 
primate models [119-125]. IFN treatment can abolish CoV infections and mouse-adapted 
SARS-CoV-infected STAT1-knockout mice show higher viral loads and pathology than wild-
type mice [126]. In the course of the evolutionary arms race, CoVs have therefore evolved 
multiple strategies to evade and antagonize the induction of IFNs and IFN signaling.  
Multiple viral nsps are implicated in evading pattern recognition. 2´O methyltransferase activity 
of nsp16 together with N7-methyltransferase activity of the nsp10/14 complex produces a 5´ 
cap structure that mimics host mRNAs and significantly reduces recognition of viral RNAs by 
MDA5 [78, 80, 127-130]. Nsp15 encodes for a domain with EndoU (uridylate-specific 
endoribonuclease) activity that cleaves viral polyuridine sequences (produced in negative- 
strand poly(A) tail transcription) to avoid recognition by MDA5 [131, 132]. Analogously, nsp14 
contributes a second mechanism to recognition evasion, by ExoN-mediated degradation of 
RNA PAMPs [75, 133]. The formation of double-membrane vesicles, a hallmark of CoV 
replication, likely contributes to evasion of pattern recognition by shielding viral replication from 
cytosolic sensor proteins, as particularly the interior of these compartments stains positive for 
dsRNA [101, 102]. In accumulation, these multidimensional strategies of pattern recognition 
evasion probably contribute to the phenotype of very low IFN induction in CoV-infected ex vivo 
lung cells [121, 134].  
In addition to the above-mentioned strategies of evading pattern recognition, CoV have 
evolved strategies to directly antagonize the activation of antiviral signaling cascades. Nsp1 of 
SARS- and MERS-CoV has been demonstrated to induce the degradation of host mRNA 
synthesis, including that of IFN-I mRNAs [135-138]. Two different motives contribute to nsp3-
mediated to immune antagonism: For SARS-CoV, the removal of the macrodomain in nsp3 
that has a ADP-ribose-1′-phosphatase domain results in an increased IFN and ISG induction 
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in infected cells by a yet unknown mechanism [139]. MERS- and SARS-CoV nsp3 further 
encode for a deubiquitinating domain, which seems to counteract the antiviral function of a 
major ISG, ISG15, and the transcriptional activity of IRF3 [140-143]. ISG and IFN promotor 
activation assays suggest an antagonistic function of SARS-CoV protein 3b, protein 6, protein 
9 and the nucleocapsid protein [144, 145]. Recently, promotor activation assays implicated 
SARS-CoV-2 nsp13, nsp14, nsp15 and protein 6 to have similar antagonistic capacity as their 
SARS-CoV homologues [146]. Promotor activation assays need to be interpreted with care, 
as artificial overexpression of single viral proteins does not reflect endogenous protein 
expression during infection. However, for SARS-CoV protein 9 additional evidence 
demonstrated protein 9-induced degradation of an important PRR signaling molecule, called 
MAVS [145]. SARS-CoV protein 6 function in IFN signaling antagonism has been clarified by 
immunoprecipitation assays that demonstrated binding and sequestration of importin alpha 1 
and beta 1, required for nuclear translocation of the ISG-inducing transcription factor STAT1 
[147]. An analogous function has evolved for MERS-CoV protein 4b, which contains a nuclear 
localization signal that competes with the transcription factor NF-kB for binding to importins 
and nuclear import [85]. MERS-CoV accessory protein 4a antagonizes IFN induction by 
binding to dsRNA and inhibiting MDA5 activation, possibly by binding to its activator PACT [86, 
148]. While initial evidence was gathered from promotor activation assays, the antagonistic 
properties of endogenous protein 4a and 4b have been clarified in the context of virus infection 




1.7 – Drivers of CoV evolution and population dynamics 
In principle, virus populations are subject to the same evolutionary drivers that shape all 
kingdoms of life: natural selection, random genetic drift and recombination. The force of natural 
selection, genetic drift and recombination correlates with the subjected population´s mutation 
rate, population size and fluctuation therein. As all of these determinants are extremely high in 
RNA viruses, RNA viruses exhibit overall evolutionary rates much higher than other organisms 
[151].  
Natural selection acts on the viral quasispecies and will select for mutations that confer the 
greatest increase in fitness, i.e. replicative success. It is therefore non-random and 
deterministic. Particularly when selection pressure is high, e.g. upon adapting to a new host, 
or upon exposure to antiviral treatment, beneficial mutations will increase in frequency and 
eventually become fixed in the virus population (positive selection or adaption), while 
deleterious mutations will decrease in frequency (negative or purifying selection). Importantly 
and frequently misunderstood, mutations themselves are stochastically more likely to exhibit 
neutral or even deleterious than beneficial effects to virus fitness [152-154].  
Genetic drift describes the random, non-deterministic process that can lead to fixation of 
random mutations by a sampling error in transmission. In viruses, genetic drift is particularly 
conceivable, since only a random minority (possibly not the representing the consensus of the 
quasispecies, therefore constituting a sample error) will infect a new cell or host to produce 
progeny and fix the transmitted genotypes [24, 151].  
Both the effect of natural selection and genetic drift are dependent on population size, which 
stringently fluctuates in virus life cycles [155]. Particularly inter-host, but also cell-to-cell 
transmission events exhibit severe bottlenecks through which only a random minority of the 
viral quasispecies will pass, followed by phases of massive population expansion in a naïve 
host. These frequent fluctuations in population size significantly expedite the effects of genetic 
drift [151, 155]. Virus population dynamics in an environment with unchanged selection 
pressure (e.g. in the same host species or not exposed to antiviral treatment) therefore tend 
to be more strongly determined by random genetic drift than by positive selection. Because of 
the stochastically increased likelihood of neutral or deleterious mutations over beneficial 
mutations, virus populations face the dilemma of a “genetic meltdown”, i.e. the continuous 
random fixation of neutral or deleterious mutations. This idea of advancing loss in fitness by 
genetic drift was particularly emanated by the geneticist H. J. Muller (†1967) in his famous 
1964 paper, in which he coined the term Muller´s ratchet as a metaphor for the unidirectional, 
stepwise loss of fitness [156-158].  
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Unsegmented RNA viruses overcome Muller´s ratchet by the process of genomic 
recombination [159, 160]. Analogously to meiotic crossing-over events in sexual reproduction, 
recombination provides asexual organisms with a tool to purge deleterious mutations from 
debilitated genomes. Mechanistically, recombination occurs upon co-infection with a related 
virus, but also within the viral quasispecies, upon random template switches of the viral 
polymerase during replication (template switch, or copy choice mechanism) [161-163]. In CoV 
evolution, the process of discontinuous transcription in sgmRNA production that involves 
template switches from the body TRS to the leader TRS, may have selected for a replication 
complex particularly prone to template switching. An additional substantial evolutionary 
advantage of recombination events, other than avoidance of Muller´s ratchet, is the possibility 
to combine unlinked beneficial mutations, in consequence creating a genome with higher 
overall replicative fitness. Linkage of beneficial mutation is of particular relevance for 
quasispecies dynamics, as individual beneficial mutations would otherwise compete with each 
other for fixation, in a process referred to as “clonal inference” [159, 161, 162, 164].  
Recombination appears to be a central aspect of RNA virus biology that has shaped the 
genomes of many RNA viruses [45, 50, 165-175]. Its importance on CoV evolution has recently 
been visualized by demonstrating that the 2002 SARS-CoV genome could have been formed 
by sequential recombination events within SARS-related CoV lineages circulating in a single 
bat colony [45].    
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2.1 – Comprehensive phenotypic  
analysis of MERS-CoV lineages 
 
2.1.1 – Introduction 
MERS-CoV phylogeny currently comprises three major clades, provisionally named clades A, 
B and C [173, 176, 177]. Whereas clades A and C contain extinct strains and strains not 
circulating in the Arabian Peninsula, clade B strains currently infect humans and camels in this 
area. Clade B is subdivided into five phylogenetic lineages. A presumed recombination 
between lineage 3 and 4 resulted in the formation of a recombinant lineage (lineage 5, also 
termed NRC for novel recombinant clade) during or before the year 2014 [172-174, 178]. As 
detailed above, recombination is a hallmark of CoV evolution and has been described for 
different CoVs infecting humans and animals [42, 44, 165, 166, 168, 169, 175]. Given that the 
current human-to-human transmission rate for MERS-CoV is close to the critical threshold for 
sustained transmission (R0 ≈ 0.6-1) [58], the emergence of a recombinant MERS-CoV lineage 
deserves critical attention. As described in chapter 1.7, recombination events may have 
beneficial effects on the recipient genome that may increase transmissibility, particularly by 
contribution of epistatic effects in linking beneficial mutations [179, 180]. 
From a public health perspective, the enzootic distribution of MERS-CoV in camels across the 
Middle East is a complex and difficult subject. Because seroprevalence studies show that 
MERS-CoV was prevalent before its incidental discovery in 2012 [53, 54], the sudden increase 
of notified cases after 2013 must be ascribed to the introduction of diagnostic tools. Reduced 
availability of diagnostics and reduced commitment of affected countries to surveillance and 
hospital infection control may have caused an apparent decline of notified cases after 2015 
[181]. Whereas the availability of notification data over a timespan of seven years (2013-2020) 
now enables a better assessment of health security risks, functional knowledge about MERS-
CoV, particularly concerning phenotypical differences between circulating lineages, is limited. 
Virological studies have been largely restricted to the reference strain EMC (for Erasmus 
Medical Centre), which pertains to a genetic lineage that was never again isolated after 2012. 
Sequencing activities and data sharing have surged since some time into 2015. Based on 
more recent studies it now emerges that since 2015 the recombinant lineage 5 has essentially 




Figure 5: MERS-CoV sequences uploaded to NCBI GenBank between 2013 and 2020. All available 
GenBank entries for MERS-CoV with a sequence length ≥5,000 nucleotides were included (n = 561). 
The collection date provided in GenBank was used for assigning a year to each sequence.  
 
This continuous circulation of a single virus clade over several years is unusual, as prior to the 
emergence of lineage 5, frequent exchange and co-circulation of clades with co-detection of 
different virus lineages even in single hospital outbreaks was the norm. The novel dominance 
of a single viral lineage therefore deserves clarification, particularly because any change of 
phenotype might indicate alterations in the already existing potential for human-to-human 
transmission. Changes of phenotype in association with lineage 5 emergence have been 
suspected, but phenotypic studies of MERS-CoV strains are generally limited. Mutations in the 
spike protein positions I529T and D510G observed during the outbreak in South Korea were 
suggested to have contributed to antibody evasion [183]. However, these polymorphisms 
evolved during and not prior to the Korean MERS-CoV outbreak and hence cannot explain the 
dominance of lineage 5 since 2015 [184]. Earlier studies looking into functional differences 
between MERS-CoV clades other than lineage 5 found little evidence for phenotypic 
differences [176, 185-187]. One complicating feature of MERS-CoV is that the infection 
phenotype as seen in humans is difficult to reflect in small animal models [188].  
In this first part of the thesis, I aimed to understand phenotypic traits of lineage 5 virus isolates, 
in using different cell-, epithelial-, and ex-vivo human lung models to compare patient virus 
isolates belonging to lineage 5 as well as the parental lineages 3 and 4. As MERS-CoV is 
























(see chapter 1.6) [85, 86, 121, 132, 189], differences in immune gene activation and 
suppression of viral replication in response to IFN signaling were studied.  
The presented studies demonstrated that lineage 5 MERS-CoV isolates replicate more 
efficiently, show decreased antiviral IRF3- and NF-kB-dependent signaling, and are less 




2.1.2 – Results 
2.1.2.1 Generation of MERS-CoV isolates from clinical samples 
obtained from Saudi Arabian patients 
Between March 2014 and November 2015 over 3,000 clinical samples were obtained from 
Saudi Arabian MERS patients. Virus isolations were attempted on 99 samples with a high virus 
load (CT-value > 25), as determined by quantitative real-time PCR (chapter 3.26) [190]. These 
99 samples were used to inoculate Vero B4 and Caco-2 cells in parallel. In 31/99 samples 
virus replication could be detected, evident by cytopathic effects (CPE) of the inoculated cells 
after 3-4 days. Virus replication was confirmed by real-time PCR, and the culture supernatant 
of these 31 samples was used to produce passage 2 working stocks (chapter 3.2). Virus stocks 
were purified using vivaspin columns 72 hours post infection (hpi) and virus titers were 
quantified by plaque titration (chapter 3.6). No plaque purification was performed to avoid the 
introduction of virus selection bottlenecks. The complete workflow for MERS-CoV isolate 
generation as applied here, including subsequent genomic analyses (chapter 2.1.2.2-2.1.2.3), 
phylogenetic analyses (chapter 2.1.2.4) and phenotypical characterizations (chapter 2.1.2.5-
2.1.2.14) is illustrated in Figure 6.  
 
Figure 6: Overview of the workflow to isolate and characterize MERS-CoV isolates, as applied in 
this thesis.  
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Quantification of virus load by real-time PCR
(N = 99/> 3,000 samples with CT-value > 25 identified)
Primary MERS-CoV isolation (N = 99)




Monitoring of virus replication
(CPE and real-time PCR) (N = 31/99) 
4
Working stock production,
purification and titration (N = 31)
5
Next generation sequencing (N = 31) 6
Full genome assembly and analyses
(N = 26/31 full genomes assembled)
7














2.1.2.2 Deep sequencing of generated MERS-CoV isolates 
Viral RNA was isolated from the 31 purified virus stocks and subjected to ultra-deep 
sequencing on a MiSeq platform (chapter 3.11). Using the Geneious software, all obtained 
NGS reads were mapped to the EMC reference genome. For 5/31 virus stocks, the NGS read 
count was insufficient to cover the full genome sequence. These samples showed an average 
of 80,000 reads, of which only 300-6,000 mapped to the EMC reference genome. Of note, 
these five virus stocks also showed the lowest viral load, which suggests that sequencing failed 
due to insufficient viral template. For 26/31 virus stocks, NGS read coverage was sufficiently 
high to assemble full genome sequences, with read counts between 1,000,000 and 1,500,000 
reads of which 600,000 to 1,200,000 reads mapped to the EMC genome.     
2.1.2.3 Genome analysis of generated MERS-CoV isolates 
No deletions/insertions or changes in ORFs were observed in any of the sequenced genomes. 
Genetic nucleotide identity was 99.8% between the assembled sequences and EMC. The 
position of single nucleotide polymorphisms (SNPs) in comparison to the reference strain EMC 
is illustrated in supplementary Figure 1. Nucleotide alignments with MERS-CoV full-genome 
sequences available in the NCBI GenBank in August 2017 were used to scan for non-silent 
SNPs in the assembled genomes, with monthly updates of sequences published later than 
August 2017. The majority of SNPs present in the generated MERS-CoV sequences mapped 
to previously published sequences. All differences in amino acid expression that are shared 
by all isolates within their respective phylogenetic lineages (see chapter 2.1.2.4) are listed in 
supplementary table 1. Five non-silent SNPs in three MERS-CoV isolates did not map to 
published sequences. One unique SNP in Riyadh-1732 2015 encodes for an amino acid 
substitution from aspartic acid to histidine at position 510 in the spike protein. D510 is located 
in the receptor-binding domain and is predicted to directly interact with the MERS-CoV 
receptor, DDP4 [191]. Changes other than histidine in that position (D510A and D510G) have 
been described to reduce receptor-binding affinity in a proposed tradeoff for reduced antibody 
recognition [183]. A second unique spike protein mutation, from glutamine to histidine at 
position 522, was identified in isolate Jeddah-9313 2014. Q522H is also located inside the 
receptor-binding domain, however it is not predicted to interact with DPP4 [191]. Two unique 
mutations mapped to nsp3 (E1050D in isolate Riyadh-1764 2015 and R859V in Riyadh-1147 




2.1.2.4 Phylogeny and recombination analysis of generated MERS-CoV 
isolates  
For taxonomic classification phylogenetic trees based on whole-genome sequences were 
inferred (Figure 7). All virus isolates clustered with either lineage 3, lineage 4 or the 
recombinant lineage 5. As expected, lineage 5 sequences branched from lineage 3 in a tree 
based on a whole-genome alignment [172, 173, 178]. Seven isolates, originating from a 
MERS-CoV outbreak in Riyadh in 2014 [192], pertained to lineage 3. In whole-genome 
alignments, these isolates showed 98.6% average nucleotide identity with published lineage 3 
strains. Eight isolates pertain to lineage 4 and originate from a 2014 outbreak in Jeddah [186] 
with 99.1% average nucleotide identity to published lineage 4 sequences. Another eight 
isolates belong to lineage 5 and stem from patients treated in Riyadh between September and 
November 2015. These lineage 5 isolates are 98.9% identical to published lineage 5 
sequences.  
Figure 7. MERS-CoV isolates from Saudi Arabian patients cluster with three distinct phylogenetic 
lineages. RaxML phylogenetic trees including reference sequences and coding-complete genomes of 












As detailed in chapter 2.1.1, MERS-CoV lineage 5 originates from a recombination event 
between lineage 3 and lineage 4 [172-174, 178]. Methodologically, detection of recombination 
between genomes is based on observation of conflicting topologies in phylogenetic trees. 
Because phylogenies give an account of similarity between sequences, recombinant genomes 
will cluster incongruently with related sequences, relative to their recombination breakpoint. 
Two different methods were used to confirm the recombination event for the MERS-CoV 
lineage 5 isolates. First, BootScan (implemented in SimPlot) was applied to construct several 
maximum likelihood phylogenetic trees for several frames of a nucleotide alignment. For each 
frame in the alignment the program indicates the percentage of congruency in each of the 
calculated trees (reported as percent of permuted trees), for each frame in the alignment. In 
an alignment with MERS-CoV EMC, lineage 3, lineage 4 and lineage 5 sequences, the 
BootScan analysis detected a clear signature of recombination for lineage 5. Lineage 5 
genomes clustered with lineage 3 sequences at genome sites 1 to 16,174 and 23,953 to 
29,714 bp, and with lineage 4 sequences from 16,175 to 23,952 bp (Figure 8A), in accordance 
with previous recombination analyses of the recombinant lineage 5 [172, 173]. As a second 
method of recombination detection, phylogenetic trees were inferred with the previously 
proposed outer and inner non-recombinant segments [173]. Both phylogenies show the typical 
pattern of topological incongruence when inferring trees from alignments that cover different 
genome portions relative to the two recombination breakpoints (Figure 8B). As expected, 
lineage 5 sequences cluster with lineage 3 sequences in trees inferred from the outer 
recombinant region, whilst they cluster with lineage 4 sequences in the inner recombinant 




Figure 8. In depth analysis of the recombination event in MERS-CoV isolates confirm 
recombination in lineage 5 A) BootScan recombination analysis based on a whole-genome alignment. 
Riyadh-1764 (lineage 5) was set as query and compared to Riyadh-146 (lineage 3), Jeddah-10306 
(lineage 4) and EMC/2012 (outlier) sequences (GenBank accession number JX869059). B) Bayesian 
phylogenetic tree based on alignments comprising concatenated 5´-proximal and 3´-distal sequences 
as indicated in the figure (left), as well as the central fragment situated between recombination 
breakpoints (right). Posterior support values are only shown if below 0.85. Viruses isolated in the present 










































2.1.2.5 Enhanced Replication of MERS-CoV lineage 5 in cell culture 
To avoid cell culture-derived selection biases, all quantitative experiments were done on 
different representative isolates per viral clade with subsequent pooling of results. 
To compare viral replication of the different MERS-CoV lineages, multi-cycle growth curves in 
Vero B4 monkey kidney cells that are widely used for diagnostic isolation of MERS-CoV were 
performed. No significant growth differences between isolates were found (Figure 9A). 
Because of the known deficiency of Vero cells in type I IFN induction, multi-cycle growth curve 
experiments were additionally performed in human lung- and colon carcinoma cell lines Calu-
3 and Caco-2, respectively. These experiments yielded up to 10-fold increased replication 
levels for all tested isolates pertaining to lineage 5. Growth was enhanced over that of the EMC 
reference strain, but also over that of all tested isolates pertaining to parental lineage 3 and 4 
(Figure 9B-C).  
Two representative isolates per lineage were tested in these experiments initially. In order to 
minimize any influence of possible inter-isolate phenotypic variability an extended range of 
virus isolates was used for the experiment in Calu-3 cells (Figure 9C). In each of four 
independent experiments summarized in the figure, infections were performed with different 
sets of two viral isolates for each lineage, resulting in each lineage to be represented by eight 
different viral isolates in the experiment (refer to supplementary Table 2 for virus isolates 
used in each experimental repetition). Overall, the tested MERS-CoV isolates pertaining to 
lineage 5 produced viral titers at least 5-fold higher than lineage 3 and lineage 4 isolates at 24 
hpi (Figure 9B and 9C). Within individual experiments, representatives of lineage 5 reached 
up to 10-fold higher infectious titers than those of lineage 3 and 4. The highly replicated 
experiment in Figure 9B yielded an average concentration of 1.23x10e5 plaque forming 
units/ml (PFU/ml) for lineage 5 isolates compared to 2.2x10e4 PFU/ml for lineage 3 and 
2.4x10e4 PFU/ml for lineage 4. All of these differences were highly significant. In addition the 
difference against MERS-CoV EMC was highly significant (p <0.0006). To better represent the 
conditions of viral replication at respiratory epithelia, polarized Calu-3 cells grown under air-




Figure 9. Enhanced replication of lineage 5 virus isolates on permanent and primary cells. Cells 
were infected at MOI = 0.002 and virus progeny in supernatant quantified by plaque assay in cell culture 
supernatants. A) Vero B4 cells, 24 and 48 hpi; B), Caco-2 colon cells, 24 hpi; C) Calu-3 lung cells, 24 
hpi; D) polarized Calu-3 lung cells grown as air-liquid interface culture, 24 hpi. Every dot constitutes the 
average of triplicate infections, performed in four (Calu-3) or two (Caco-2, Vero B4 and polarized Calu-
3 cells) independent experiments on different days. Statistical significance in difference of PFU/ml 
between MERS-CoV lineage 5 and other lineages was determined by Krustall-Wallis test in A) (*P > 
0.0332, ns P < 0.05), and by two-tailed t-test in B), C) and D)  (**P < 0.0021; ***P < 0.0002; ****P < 
0.0001). 
2.1.2.6 MERS-CoV lineage 5 has enhanced competitive replicative 
fitness  
Cell culture growth kinetics can be limited by systematic and random errors, which can be 
partially controlled for by competitive replication studies in which viral isolates compete in a 
single culture dish [193, 194]. A given virus is likely to have superior relative fitness if it can 
become dominant in a virus population in spite of starting as a minority population in the initial 
virus seed dose [24]. To test this, Calu-3 cells were infected with a mixture of representative 
virus of lineage 5 and lineage 3, serving as the competitor, in two different ratios (1:1 and 9:1; 
lineage 3 : lineage 5). The total infectious dose in these cultures was 10,000 PFU, 
corresponding to an intermediate MOI = 0.04 which enables a short multi-cycle growth 
experiment while avoiding stochastic errors in the seed dose. As the total virus amplification 
may be too limited to detect shifts in lineage ratios when starting from this seed dose, four 
additional amplification cycles were done. In preliminary experiments, such as multi-cycle 
infection experiment detailed in chapter 2.1.2.5, the yield of infectious virus progeny when 
infecting Calu-3 cells at MOI = 0.04 was determined to be in the range of 10e4-10e5 PFU/ml 
at 24 hpi. Therefore, 24 hpi supernatants were diluted to a new seed dose of approximately 
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1,000-10,000 PFU and used as an inoculum for a second passage. This process was repeated 
until a completion of five passages. Viral RNA was isolated from the initial inoculum (p0) and 
from the supernatant after five passages (p5) and directly sequenced with two different single 
nucleotide polymorphisms (SNP) sites that were each amplified from the virus population in 
three separate RT-PCR reactions to control for PCR-based artifacts.  
Based on Sanger sequencing, peak heights of the sequencing reaction was analyzed with the 
web-based Chromat Quantitator (Mullins lab, University of Washington; chapter 4.12) to 
quantify how much of each virus lineage was present at p0 and p5 (Figure 10A). The ratio of 
virus progeny at p5 was found to shift in favor of lineage 5 (Figure 10B) in all cases, which 
strongly argues for an increased replicative fitness of lineage 5 MERS-CoV isolates. 
 
 
Figure 10:  Lineage 5 outcompetes a parental virus strain of lineage 3 in an in-vitro fitness 
competition assay. Calu-3 cells were infected in duplicates with 10,000 PFU containing the indicated 
ratios of a lineage 3 : lineage 5 virus isolate at the time of initial infection (p0). 1,000-10,000 PFU were 
transferred in 5 subsequent passages. A) At p0 and p5, viral RNA was isolated from the 
inoculum/supernatant and two RT-PCRs over two SNP that discriminate lineage 3 and lineage 5 were 
performed. RT-PCR amplicons were subjected to Sanger sequencing over the respective SNPs to 
investigate changes in sequencing chromatograms. B) average peak heights in sequencing 
chromatograms at each SNP were analyzed using the Chromat Quantitator server and compared 
between p0 and p5 populations 
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Analysis of stages of viral replication cycle 
Multiple factors could be responsible for enhanced MERS-CoV growth in cell cultures, 
including improved virus attachment, entry, transcription, replication, infectious particle 
production, or innate immune counteraction.  
In the following sections, it was delineated which parts of the virus life cycle contributes to the 
increased replication observed in the lineage 5 isolates.  
2.1.2.7 MERS-CoV EMC and lineages 3, 4 and 5 show similar host cell 
entry 
The spike protein mediates attachment and entry into host cells via the host receptor DPP-4 
[81]. Its N-terminus additionally mediates virus attachment via sialic acid domains [89]. 
Comparison of viral sequences provide no indications for the involved spike proteins to differ 
in their sialic acid-binding and receptor-binding properties. All spike sequences are identical to 
each other with the following exceptions (Supplementary Figure 2): lineage 3 genomes 
uniquely encode for a L411F substitution, situated in the receptor-binding domain (RBD). The 
RBD domain is responsible for binding to the entry receptor, consequently mutations in the 
RBD may influence receptor binding. However, previous studies of the L411F polymorphism 
demonstrated unaltered binding affinity and entry efficiency for this polymorphism [183].  
Lineage 4 genomes uniquely encode for a Q833R substitution. Position 833 lies outside of the 
RBD and is therefore unlikely to have phenotypic consequences. All three lineages are distinct 
from the EMC reference strain by the Q1020R mutation that is shared among all MERS-CoV 
sequences pertaining to phylogenetic clade B. The spike protein N-terminus is identical in all 
four lineages and no differences in glycosylation that could influence sialic acid binding affinity 
were predicted in silico, using the NetNGlyc and NetOGlyc server (see chapter 4.12). All three 
lineages are predicted to have three O-glyocsylations in total, two at the N-terminal domain 
and one at the C-terminal domain. Nine significant hits were detected for N-glycosylation in all 
three lineages, with the majority being present in the N-terminal domain, as expected [89].  
2.1.2.8 MERS-CoV EMC and lineages 3, 4 and 5 show similar host cell 
entry capacity and DPP4-binding  
In order to verify the sequence-informed hypothesis that the spike proteins of lineage 3, 4 and 
5 do not differ in their capacity to mediate host cell entry and receptor-binding, expression 
vectors carrying the spike proteins of lineage 3, lineage 4 and lineage 5 were cloned and 
incorporated into a rhabdoviral vesicular stomatitis virus (VSV)-based pseudotyping system 
[183]. The VSV system enables a quantitative assessment of entry capacity, as each 
pseudotyped particle transduces target cells with a firefly luciferase (fLuc) gene upon cell entry. 
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Fluc activity in transduced cells therefore serves as a direct correlation of how efficiently the 
transfected spike protein gene facilitates host cell entry.  
No significant differences in host cell entry capacity was observed between the pseudotyped 
VSV particles (Figure 11A-C). Entry capacity was tested in cell lines expressing high and low 
amounts of TMRPSS2 (high: Calu-3 and Caco-2, Figure 11A and 11B; low: Huh7, Figure 
11C) to account for entry capacity with protease primed and non-primed spike protein [195]. 
In order to determine differences in DPP4-binding capacity of each spike, lineage-specific 
spike genes were expressed in 293T cells and incubated with varying concentrations of soluble 
human DDP4. Subsequently, bound DPP4 was incubated with a Fluorophore-conjugated anti-
human antibody, which was quantified by flow cytometry. No significant differences in DPP4-
binding capacity between the spike proteins of each lineage were found (Figure 10D). 
 
 
Figure 11: lineage specific MERS-CoV spike proteins show no difference in host cell entry and 
DPP4-binding capacity. A-C) rhabdoviral particles harboring MERS-CoV spike proteins of the EMC 
isolate, lineage 3, lineage 4 and lineage 5, VSV-G (positive control), or eGFP (negative control) were 
inoculated onto TMPRSS2 expressing Calu-3, Caco-2 and TMRPSS2 negative Huh7 cells. 
Transduction efficiency was quantified at 18 hours post transduction by measuring the activity of virus-
encoded luciferase in cell lysates. Transduction mediated by EMC spike protein was set as 100%. The 






























































































































































































































































































indicate SEMs. Statistical significance was analyzed by paired two-tailed Student´s t-tests. D) 293T cells 
transfected to express MERS-CoV lineage-specific spike proteins or empty expression vector (pCG1) 
were detached and incubated with human Fc-tagged, soluble DPP4 (solDPP4-Fc), diluted 1:50, 1:200 
and 1:1,000 and an Alexa Fluor 488-conjugated anti-human antibody before DPP4-binding was 
quantified by flow cytometry. For normalization, binding of 1:200 solDPP4-Fc to EMC spike was set as 
100%. For background subtraction of samples incubated with just Alexa Fluor 488-conjugated 
antibodies (control) was performed for each sample. EMC spike carrying the I529T SNP was included 
as an internal control, since this SNP has been previously shown to reduce DPP4-binding [183]. The 
results of a single representative experiment carried out with triplicate samples are shown and were 
confirmed in a separate experiment. Error bars indicate SDs. 
 
As viral proteins other than the spike protein may influence the entry process, infection assays 
in Calu-3 cells using virus isolates were performed, in a single-cycle infection (MOI = 1). 
Intracellular genomic RNA uptake 1 hour and 4 hours after virus absorption was quantified by 
real-time PCR. All cell cultures were infected at 4°C to ensure that cell entry initiation is 
simultaneously achieved by a temperature shift to 37°C. Genomic RNA as well as sgmRNA N 
were quantified as an early and sensitive indicator of the onset of transcription after the 
conclusion of the entry process. As a control, several stages of MERS-CoV entry were 
simultaneously blocked using inhibitors of clathrin-mediated endocytosis (classical entry 
pathway), host membrane serine proteases (alternative entry pathway via direct fusion with 
the plasma membrane), as well as endosomal proteases (downstream endosomal fusion). 
No significant differences in genomic and sgmRNA quantities among all virus lineages were 
detected 1 and 4 hours post binding (Figure 12). Chemical blocking of virus entry revealed 
that all four lineages had entered into the stage of sgmRNA transcription by 4 hours post 
adsorption, without discernible difference in transcription levels.  
 
Figure 12. All tested MERS-CoV strains show similar host cell entry. Calu-3 cells were infected in 
duplicates with one virus isolate of all each phylogenetic lineage (EMC, lineage 3, lineage 4 and lineage 
5) at MOI = 1 in the presence or absence of CoV entry inhibitors. Entry inhibited samples were pre-
incubated for 1 hour with a cocktail of 25 µM Cathepsin L inhibitor, 25 µM Pitstop II, and 100 µM 
Camostat mesylate. The inhibitor cocktail remained on the cells during the whole course of infection. To 



































































washing steps with PBS. After virus attachment, infected Calu-3 cells were either immediately lysed (0 
hpi), or incubated at 37°C for 1 hour or 4 hours, respectively (1 hpi and 4 hpi, respectively). Total RNA 
was isolated from lysed cells and viral genomic RNA (ORF1a) and sgmRNA N was quantified by real-
time qPCR and plotted relative to the amount of the housekeeping gene TBP. The inocula of each 
phylogenetic lineage were back-titrated by plaque assay to confirm that highly similar amounts of 
infectious particles were used to infect the cells. 
2.1.2.9 All MERS-CoV lineages are comparably neutralized by anti-
MERS-CoV-positive human and camel sera 
Because neutralizing antibodies may act via proteins or domains other than the spike N-
terminus and RBD, serum neutralization based on a highly sensitive plaque reduction 
neutralization assay (PRNT) on live viruses was tested. If antibody-mediated virus 
neutralization was different between the lineages, this would imply that different dilutions of 
sera are required for a 50% reduction in plaques. However, all virus isolates were neutralized 
with equal efficiency, i.e. the same serum dilution factor, by human (N=2) and camel (N=3) 
sera as summarized in Table 1 [11].  
Table 1. Plaque reduction neutralization assays (PRNT50 dilutions) with five sera for four MERS-
CoV isolates.  














(MERS patient, Germany 2014) [196] 
1:1,280 1:1,280 1:1,280 1:1,280 
SA278 
 (MERS patient, KSA 2014) [187] 
1:2,560 1:2,560 1:2,560 1:2,560 
Dubai-S1  
(camel, UAE 2014) [197] 
1:10,240 1:10,240 1:10,240 1:10,240 
Kenia-ILRI  
(camel, Kenya 2017) [54] 
1:5,120 1:5,120 1:5,120 1:5,120 
Pakistan-493 
 (camel, Pakistan 2015) [198] 
> 1:10,240 > 1:10,240 > 1:10,240 > 1:10,240 
 
*indicated viruses were neutralized with two human sera and three camel sera as indicated. The data 
indicate serum dilutions at which 50% of plaque forming units are neutralized as compared to control.  
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2.1.2.10 MERS-CoV lineage 5 shows an earlier commencement of 
replication 
The above-mentioned experiments used synchronized infections at high MOI. Next, multi-
cycle, low MOI replication experiments were performed in Calu-3 and Vero B4 cells, to ensure 
that the early phase of replication is less masked by input viral RNA. Virus inoculation of cells 
was done at 4°C to allow virus particle attachment to the cellular receptors before simultaneous 
cell entry was induced by shifting the temperature to 37°C. sgmRNA transcripts of the 
nucleocapsid gene (sgRNA N) were quantified as an indicator for early virus transcription 
whereas genomic ORF1a-specific RNA was detected to monitor the onset of full virus genome 
replication. Additionally, PFU/ml were quantified in the supernatant to analyze differences in 
virus particle formation and egress (Figure 13). 
Overall, there was little difference between sgRNA N and genomic ORF1a transcript 
quantification, which is plausible considering that both are copied from the same template and 
replicative intermediates accumulate in parallel [121]. Virus infections in Calu-3 cells showed 
an earlier onset of replication than in Vero B4 cells, which may be attributable to the availability 
of TMPRSS2 providing an additional entry pathway in Calu-3 cells [199]. Already from the 
beginning of detectable replication, lineage 5 viruses showed a higher level of RNA 
transcription than the parental lineages 3 and 4. Enhanced infectious virus production of 
lineage 5 was only seen in Calu-3- but not in type I IFN-deficient Vero B4 cells, which 
corresponds to the previous observations in multi-cycle infection experiments (Figure 9). 
Figure 13. sgmRNA N, ORF1a and PFU quantification at early stages of infection. A) Calu-3 and 
B) Vero B4 cells were infected at an MOI of 0.002 with one virus isolate of each phylogenetic lineage in 
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duplicates for each indicated time point. At the indicated time points, cell culture supernatant was 
collected and subjected to virus quantification by plaque assay. Infected cells were lysed and total RNA 
was isolated to be subjected to quantification by real-time PCR of sgRNA N and ORF1a RNA. Cycle 
thresholds were normalized to the housekeeping gene TBP and the amount of RNA at 0 hpi.  Statistical 
significance of differences in virus replication was analyzed by Mann-Whitney test (p-value <0.0332;*). 
2.1.2.11 MERS-CoV lineage 5 shows reduced cytokine induction  
Results up to this point suggested that lineage 5 has a higher intrinsic replication level than 
viruses belonging to parental lineages. To explore if higher replication triggers a higher 
cytokine induction, Calu-3 cells were infected with two viruses of each phylogenetic lineage in 
a single-cycle, high MOI infection. mRNA expression levels were analyzed for a set of immune-
related genes at 12 hpi. IRF3-regulated genes IFNB1 and IFNL1, NFkB-regulated genes CCL5 
and TNFA, as well as IFN-stimulated gene Mx1 were included to reflect various common 
pathways in antiviral innate immunity. To enable single-cycle virus infection, cells were infected 
at MOI = 2 (Figure 14A). Under these conditions, the two lineage 5 isolates used in the 
experiment replicated to a higher 4.4- and 7.7-fold level than the MERS-CoV isolates of lineage 
3 and 4, respectively (two strains each). Intriguingly, lineage 5 induced significantly lower levels 
of IFNs and CCL5 mRNA compared to isolates pertaining to lineage 3 and 4 (Figure 14B). 
Immune gene mRNA induction in general seemed to be highest with lineage 3 strains. Average 
IFNB1 levels were reduced 12.4 and 3.1-fold and average IFNL1 mRNA expression was 
reduced 3.7- and 1.4-fold in Calu-3 cells infected with lineage 5, over Calu-3 cells infected with 
lineage 3 and 4 virus isolates, respectively. Average CCL5 transcripts were induced 2.9- and 
2.1-fold in cells infected with lineage 5, over cells infected with lineage 3 and 4 virus isolates, 
respectively. 
Figure 14. Lineage 5 MERS-CoV strains show reduced immune gene induction. Calu-3 cells were 
infected with two isolates of each phylogenetic lineage with a high multiplicity of infection (MOI = 2) for 






































































production as quantified by plaque assay 12 hpi. B) immune gene induction as quantified by real-time 
RT-PCR on lysed Calu-3 cells 12 hpi, expressed as fold induction over the non-infected control cells, 
normalized to the housekeeping gene TBP. Statistical significance of differences in virus replication was 
analyzed by Mann-Whitney test (p > 0.05, ns; p ≤ 0.05, *; p ≤ 0.01, **; p ≤ 0.001, ***).  
2.1.2.12 MERS-CoV lineage 5 is less sensitive to IFN treatment 
Previous studies have shown that MERS-CoV EMC is highly sensitive towards type I IFN pre-
treatment [52]. To analyze IFN sensitivity among the different MERS-CoV lineages, virus 
replication was monitored in Calu-3 cells pre-treated with type I IFN for 16 hours. IFN 
concentrations were chosen to induce mainly an upregulation of cellular helicases (2.5 units 
IFN), as well as IFN concentrations high enough to induce a complete antiviral state (25 units) 
in treated Calu-3 cells.  
Replication of the reference strain EMC was already suppressed by low level IFN pretreatment, 
in accordance to published results [120]. Lineage 3 strains showed similarly high IFN 
sensitivity, while lineage 4 and lineage 5 strains were not suppressed by 2.5 units of IFN 
(Figure 15). 25 units of IFN markedly reduced virus replication of all lineages. The reduction 
of replication caused by this dose was 6.5-fold for lineage 5 and 23- and 18-fold for virus 
isolates pertaining to lineage 3 and 4, respectively. 
 
Figure 15. Lineage 5 MERS-CoV isolates show decreased IFN sensitivity. Calu-3 cells were 
incubated for 16 hours with 2.5 or 25 units type-I IFN prior to infection at MOI = 0.002 with two MERS-
CoV isolates of each indicated lineage in triplicates. Inocula, as well as virus progeny in supernatant 24 
hpi were quantified by plaque assay. Shown are the combined data of two independent experiments 
with error bars indicating the SD.  Statistical significance of differences in virus replication was analyzed 
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2.1.2.13 Increased replication of MERS-CoV lineage 5 is not exclusively 
correlated to antagonism of JAK/STAT signaling  
To investigate if lineage 5 viruses show a lower IFN sensitivity due to increased antagonism 
of IFN signaling alone, Calu-3 cells were infected with lineage 3, 4 and 5 virus isolates in the 
presence of the JAK/STAT inhibitor Ruxolitinib (Figure 16A). Additionally, virus replication was 
compared in MERS-CoV-susceptible T84 cells carrying an IFN-alpha and -lambda receptor 
double knock-out (Figure 16B). Whereas control experiments confirmed the higher replication 
levels of lineage 5, both approaches to IFN receptor inactivation caused lineage 5 strains to 
lose a minor part of their replicative prominence. Overall, lineage 5 strains retained a 
significantly higher replication level than strains pertaining to lineage 3 and 4, suggesting that 
IFN signaling alone does not explain the observed differences.  
  
Figure 16: Replication of MERS-CoV isolates in JAK/STAT signaling inhibited and IFN receptor 
knock-out cells. Higher replication of lineage 5 MERS-CoV is additionally linked to IFN action via the 
JAK/STAT signaling pathway. A) Calu-3 cells were treated with 50 nM of the JAK/STAT inhibitor 
Ruxolitinib 1 hour prior and during the infection with two viruses per phylogenetic lineage (lineage 3, 
lineage 4 and lineage 5) in duplicates. Virus progeny in the supernatant was quantified by plaque assay 
at 24 hpi. Statistical significance of differences in virus replication was analyzed by Mann-Whitney test 
(**P ≤ 0.0021, ***P ≤ 0.0002). B) T84 wt and type I and III IFN receptor knock-out cells (IFNAR/IFNLR 
KO cells) were infected in triplicates. Virus progeny in the supernatant was quantified by plaque assay 
at 24 hpi. Statistical significance of differences in virus replication was analyzed by Mann-Whitney test 








































































2.1.2.14 MERS-CoV lineage 5 shows increased replication in models of 
the human respiratory tract  
To more closely reflect virus replication in the respiratory tract [41], fully differentiated human 
airway epithelia (HAEs) were infected with two representative isolates from each phylogenetic 
lineage. According to previous observations supernatants were samples exclusively from the 
apical site of differentiated HAE were sampled and virus progeny was quantified every 24 
hours for four subsequent days [45]. Lineage 5 isolates reached average titers up to 15-fold 
higher compared to lineage 3, lineage 4 and the EMC reference strain, with significant 
differences at 24 and 48 hpi (Figure 17A). To provide a model of infection that most closely 
resembles infection of the human lung, ex-vivo infections were performed in human lung 
explants, derived from patients that have undergone lung resection. One representative virus 
isolate per phylogenetic lineage was included to infect lung explants derived from three 
different donors (Figure 17B). Supernatants of infected lung explants were harvested at 16, 
24, 48 and 72 hpi. Similar to HAEs, lineage 5 reached titers up to 5-fold higher compared to 
lineage 3, lineage 4 and the EMC reference strain, with significant differences at 24 and 48 hpi 
(Figure 17B).  
    
Figure 17. Growth kinetics of MERS-CoV isolates in models of the human respiratory tract. A) 
Replication on primary human airway epithelium (HAE) of a single donor. Two isolates of each 
phylogenetic lineage were used for infection in triplicates. Virus progeny in apical washes was quantified 
by plaque assay every 24 hours by plaque assay. Statistical significance in difference of PFU/ml 
between lineage and other lineages was determined by two-tailed Mann-Whitney test (**P < 0.0021). 
Statistical significant differences in PFU/ml were found at 24 hpi for lineage 5 between lineage 3 (**) and 
EMC (*); at 48 hpi between lineage 5 and lineage 3 (**), lineage 4 (**) and EMC (*); at 72 hpi between 
lineage 5 and lineage 3 (*) and lineage 4 (**). B) Growth kinetics of MERS-CoV isolates on lung explants, 
derived from three different patients that have undergone lung resection. One isolate of each 
phylogenetic lineage was used for infection in triplicate for each explant and virus progeny in the 
supernatant was quantified by plaque assay. Differences in PFU/ml between lineage 5 and other 
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2.1.3 – Discussion 
The present comprehensive in vitro and ex vivo studies with clinical MERS-CoV isolates 
reflecting virus lineages prior to and past the shift towards the recombinant lineage 5, 
demonstrate a higher replicative fitness of MERS-CoV lineage 5 isolates over previously 
circulating lineages, as a function of lower level of cytokine induction and IFN resilience.  
Since 2015, lineage 5 was highly prevalent in sampled dromedary camels and humans in 
Saudi Arabia, and caused a major outbreak in South Korea [172-174, 200]. This upsurge 
triggered speculations as to the transmissibility of the novel virus variant. Nevertheless, the 
phenotype of these viruses, as opposed to viruses circulating earlier, has not been studied to 
date. The data presented in this part of the thesis provide the first comprehensive phenotypical 
assessment of lineage 5 isolates, and reveal changes that likely correlate with transmissibility 
and pandemic potential. Primarily, higher relative fitness and increased replication levels may 
translate into higher excreted virus doses during infection. Transmission of higher average 
doses will inevitably increase the viral capability to adapt to humans [24, 201]. As detailed in 
chapter 1.7, virus transmission from one host to another constitutes a bottleneck through which 
only the excreted minority of the virus population will pass [202]. If a higher average virus dose 
is excreted, the chances that a more adaptive variant will pass through the bottleneck are 
increased. Secondly, reduced cytokine induction as observed here is considered an indicator 
of increased virulence and major determinant in overcoming species barriers (reviewed in 
[203]). 
One can conclude from the performed experiments that the increased fitness of members of 
lineage 5 does not result from changes affecting viral entry and is unlikely to be based on an 
altered interference with IFN receptor-dependent signaling. Most likely, the differences in this 
part are caused secondarily due to clear differences in either infection sensing or downstream 
elements of cytokine induction cascades. Any functional diversity of circulating MERS-CoVs 
on the Arabian Peninsula is somewhat surprising given that earlier studies found little indication 
for phenotypic differences between viral lineages [176, 178, 186, 204]. A study of African 
viruses found functional diversity [176] that could be attributed to deletions in ORF4b encoding 
a suppressor of RNAse L that acts via an active phosphodiesterase function [85, 150, 189]. 
However, the present viruses have a full gene repertoire and thus provide little angle to link 
changes of phenotype to any defined gene target. Viral proteins that have previously been 
associated with innate immune antagonism in MERS- and related CoVs, including nsp1, nsp3, 
nsp14, nsp15, nsp10/16, p4a and p4b are fully conserved in the present lineages or show 
amino acid substitutions unlikely to affect protein function (i.e. no addition/loss of charge or 
polarity or bulkiness, supplementary Table 1 [85, 86, 132, 135, 141, 150, 189]. 
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The further search for mechanisms to explain the viral phenotype and host response will 
therefore have to involve comprehensive studies such as shuffling of gene portions based on 
reverse genetics. Identifying causal mutations will help to understand whether and how 
cooperating mutations may have been assembled into one genome following recombination, 
and how the recombinant virus phenotype was selected for. Mapping those causal mutations 
to functional domains within the viral genome might even be used to assess the pathogenicity 
of future emerging MERS-CoV. Novel reverse genetic systems, such as in yeast cloning by 
transformation associated recombination (TAR cloning) may help to overcome the technical 
hurdles of shuffling large genome sections and have been already been initiated [205].  
It should be clearly understood that the observed phenotype of lineage 5 does not constitute 
evidence for selection in humans. Analyses of viral populations have led to the conclusion that 
human-to-human transmission does not currently play a relevant role in MERS-CoV 
evolutionary dynamics, and selection therefore will have taken place in the animal reservoir 
[180]. However, the reduced induction of cytokine expression is compatible with selection in 
dromedary camels as immune sensors and appending signal transduction cascades triggering 
cytokine induction are conserved among mammals [206, 207]. Selection for virulence in 
dromedary camels may involve a collateral benefit for the virus once transmitted to humans. 
Importantly, increased virus dose in the camel population increases the likelihood of spillover 
events and hence heightens the zoonotic potential of the recombinant MERS-CoV lineage 5 
over previously circulating lineages.   
In the light of virus population dynamics, the emergence of a recombinant virus lineage with 
increased fitness is an intriguing piece of evidence that recombination events may have 
functional relevance on virus populations, other than purging deleterious mutations from the 
genome (chapter 1.7) [151]. An example of recombination between CoV lineages giving rise 
to a more pathogenic strain has been provided by the cases of feline CoVs and IBV [34, 35]. 
To the best of my knowledge, the present study is the first report of a recombinant CoV lineage 
with a change of phenotype in humans. Its occurrence in MERS-CoV is particularly relevant 
from a public health perspective, as the current human-to-human transmission rate for MERS-
CoV is close to the critical threshold for sustained transmission (R0 ≈ 0.6-1) [58, 59]. As detailed 
in the chapter 1.7, recombination events may introduce shifts in a population´s fitness 
landscape that are of larger scale than genetic drift alone, and may therefore increase the 
stochastic potential for a more transmissible stain to emerge. Future studies should address 
which viral factors are responsible for the increased fitness of lineage 5. The recombination 
event may itself be causal if individually neutral or beneficial mutations from donor lineages 
were shuffled together to increase fitness though epistasis. Virus population dynamics are 
driven by clonal inference, i.e. the within a quasispecies occurring competition of beneficial 
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mutations for the fixation in the population, rendering changes in fitness sequential [208]. 
Conceivably, beneficial variants were already competing for fixation in lineage 3 and 4 and the 
recombination event alleviated these variants from clonal inference in fusing beneficial 
mutations, resulting in overall increased fitness. In that line, there is some evidence from the 
data presented here that members of the parental lineage 4 show an attenuated cytokine-
based immune response, but these viruses do not show increased overall fitness (chapter 
2.1.2.11 and 2.1.2.12). Alternatively, fitness-increasing mutations might have occurred after 
the recombination event. It is conceivable that the recombination event caused drastic 
alteration in fitness landscape that enabled the exploration of secondary mutations, which may 
have diversified the viral quasispecies and therefore may have increased the probability for a 
fitter variant to be selected for (survival of the flattest theory) [209]. However, for most RNA 
virus species an upsurge of mutations is deleterious to fitness [26-29]. Yet, there is some 
evidence that natural selection works on viral quasispecies as a whole, opposed to single 
mutant variants of the “cloud”, and that a diversified quasispecies itself may grant fitness 
advantages [210]. For all lineage 5 genomes that were sequenced here, I obtained a 
sequencing read coverage deep enough to detect minority variants (chapter 2.1.2.2). However, 
in highly stringent NGS read consensuses, there was no evidence for a diversified 
quasispecies that may have been detectable as an increase of nucleotide ambiguities in 
lineage 5 sequencing data over other lineages. To exclude quasispecies diversity as the driver 
for increased fitness in lineage 5, in depth analysis of existing sequencing data should be 
performed and complemented with sequencing techniques that enable discrimination between 
false reads and real minorities [211-213].   
It is a limitation of the present study that a deeper mechanistic investigation cannot be 
provided. It should be noted that the observed differences in virus-host interaction may 
originate outside the direct infection sensing and cytokine induction mechanisms, so that 
changes in cytokine induction as well as the partial differences in IFN sensitivity might be 
collateral effects. Particularly a functionally increased replication complex that changes the 
expression pattern of viral immune antagonists is conceivable. Early or increased expression 
of viral antagonists could promote overall fitness by increased reduction of the antiviral host 
responses. Comprehensive studies of the replication complexes of each MERS-CoV lineages 
could delineate a possible correlation of increased replication and reduced antiviral signaling 
induction. Such studies would require the establishment of complex reporter-coupled replicon 
systems for each MERS-CoV lineage by reverse genetics.    
Under the impressions of an ongoing SARS-CoV-2 pandemic, the emergence and 
epidemiological dominance of a more replicative strain of MERS-CoV should be acknowledged 
by public health authorities and warrants an increased surveillance of circulating MERS-CoV 
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species. Comprehensive studies on the biology and evolution of pre-pandemic CoV species 
as provided in this thesis can contribute to our understanding of the dynamics of emergence 




2.2 – Phenotypic comparison of SARS-CoV- and 
SARS-CoV-2-specific IFN antagonism 
 
2.2.1 – Introduction 
SARS- and SARS-CoV-2 pertain to the same virus species, the SARS-related CoVs, within 
the genus Betacoronavirus [52]. However, SARS-CoV-2 shows features distinct to SARS-CoV 
in its clinical and epidemiological presentation, with lower pathogenicity and case fatality rate 
but substantially higher human-to-human transmission rate and incidence [68]. Both viruses 
show an identical genomic architecture with a homologous set of ORFs, however the amino 
acids encoded in the ORFs are not identical in sequence [66]. Consequently, putative 
determinants of differential pathogenicity and transmission capacity might be linked to the 
amino acid divergence of these ORFs.  
There is good evidence that the increased human-to-human transmission rate of SARS-CoV-
2 is a function of tissue tropism [67, 93, 214]. Clinical observations suggest that SARS-CoV-2 
is replicating in –and importantly is shed from- the upper and lower respiratory tract, while 
SARS-CoV mainly replicates in the lower respiratory tract, despite identical receptor usage 
[214]. Recent studies imply that the differential tissue tropism correlates with spike protein 
divergence. As detailed in chapter 1.5, the SARS-CoV spike protein might interact with the 
host protease TMPRSS2 to employ the preferred and more efficient cell entry route of particle 
fusion at the plasma membrane [67, 92, 95]. A striking feature of the SARS-CoV-2 spike protein 
is a polybasic amino acid stretch (RRAR) at position 813 to 816, upstream of the S2 domain 
that mediates membrane fusion. Nascent SARS-CoV-2 spike proteins probably undergo furin-
mediated pre-cleavage at this polybasic amino acid stretch, which primes the SARS-CoV-2 
spike proteins for preferential TMPRSS2-mediated entry at the plasma membrane [93]. 
Further, an overall higher binding affinity of SARS-CoV-2 spike protein to the cellular receptor 
ACE2 was demonstrated, yet the contribution of divergent amino acids in the RBD remains to 
be clarified [215]. In synopsis, the altered tropism and increased transmissibility of SARS-CoV-
2 might be a function of spike protein divergence and cellular co-factor distribution, particularly 
of TMRPSS2, which is highly abundant in the upper respiratory tract [67, 93, 216]. Of note, a 
similar mechanism of pre-egression furin-mediated spike cleavage is also employed by the 
MERS-CoV spike protein [99], yet DDP4 expression, in contrast to ACE2 expression, is limited 
to the lower respiratory tract [217].  
If and how broader host tropism of SARS-CoV-2 contributes to pathogenicity remains elusive. 
A major driver of virus pathogenicity other than cell entry capacity is the evasion of innate 
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immunity. As detailed in chapter 1.6, type I IFNs are among the first cytokines to be 
upregulated in virus-infected cells and play a key role in determining the outcome of infections 
by orchestration of the antiviral and inflammatory response. IFN signaling triggers the 
expression of over 300 antiviral proteins and chemokines, inducing an antiviral state in host 
cells [116]. Resilience towards IFN-mediated innate immunity seems to be associated with 
virulence and pathogenicity in many virus families [218]. As detailed in chapter 1.6, SARS-CoV 
is highly sensitive towards IFN treatment and evolved multiple mechanisms to counteract the 
induction of IFN and IFN signaling [122, 123]. Therefore, protein sequence divergence 
between described (and unknown) viral IFN antagonist may exhibit effects on the immune 
evasion phenotype of SARS-CoV-2 that might account for the distinct clinical presentation of 
SARS- and SARS-CoV-2.  
In this part of the thesis, the IFN evasion phenotypes of SARS-CoV and SARS-CoV-2 were 
compared by focusing on differences in IFN induction and signaling. Evidence for a relatively 
lower IFN induction antagonism by SARS-CoV-2 could be functionally correlated to protein 6, 
as infection studies with mutant viruses, produced by reverse genetics, implicated that SARS-




2.2.2 – Results 
 
2.2.2.1 Replication kinetics of SARS-CoV-2 and SARS-CoV in IFN 
competent and incompetent cell lines 
In search for suitable cell culture systems to study the newly emerged and largely unknown 
SARS-CoV-2, the human bronchial cell line Calu-3 and the primate kidney cell line Vero E6 
were tested for their capacity to support replication of both SARS-CoV and SARS-CoV-2.   
Intriguingly, there was a striking cell line specificity in the ability to support replication of SARS-
CoV and SARS-CoV-2. In Vero E6 cells that lack type I IFN genes [219], SARS-CoV grew to 
36-fold higher titers than SARS-CoV-2 when inoculated with an MOI of 0.001. In Calu-3 cells 
that have a functional IFN response [220], SARS-CoV-2 infection yielded 5-fold higher titers 
compared to SARS-CoV at 24 hpi (Figure 18A). SARS-CoV and SARS-CoV-2 induced 
stronger cytopathic effect in Vero E6 and Calu-3 cells, respectively, which corresponded to the 
differential viral growth (supplementary Figure 3). 
To shed light on these cell line-specific observations, the impact of a blunted type I IFN 
signaling was determined for both viruses. Treatment with the STAT1 phosphorylation inhibitor 
Ruxolitinib enhanced infection by both viruses in Calu-3 cells, as judged by quantification of 
double-stranded RNA replication intermediates and infectious particle production, suggesting 
that both viruses are sensitive to a naturally induced IFN-mediated antiviral response (Figure 





Figure 18. SARS-CoV-2 and SARS-CoV are sensitive to the IFN response. A) Multi-cycle infections 
(MOI = 0.001) of SARS-CoV-2 (strain Munich/2020/984; BetaCoV/Munich/BavPat1/2020 
|EPI_ISL_406862) and SARS-CoV (strain Frankfurt (Fra); GenBank accession number AY310120) in 
the primate kidney cell line Vero E6 (left) and the human bronchial epithelial cell line Calu-3 (right). Viral 
titers in the culture supernatant were quantified by plaque titration on Vero E6 cells at 0, 24 and 48 hpi. 
Four experiments in duplicate infections were pooled. Statistical significance in difference of PFU/ml 
between SARS-CoV-2 and SARS-CoV PFU/ml was determined by two-tailed t-tests (p-value 
<0.0001;****). B and C) Virus replication under the influence of 100 nM of the JAK STAT inhibitor 
Ruxolitinib (Invivogen) as determined by plaque titration of SARS-CoV-2 and SARS-CoV in Calu-3 cells 
24 hpi (MOI = 0.001). Immunofluorescent dsRNA staining was performed in Calu-3 cells at an MOI of 
0.01 at 16 hpi. dsRNA signal intensity quantification was performed in ImageJ using six microscope 
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2.2.2.2 SARS-CoV-2 is more sensitive towards IFN treatment than 
SARS-CoV 
For a quantitative assessment of IFN sensitivity, virus replication was compared in both cell 
lines after pre-infection or post-infection treatment with IFN-beta in increasing concentrations 
(Figure 18). To account for the cell line-specific differences in virus propagation capacity 
detailed in chapter 2.2.2.1, replication levels were normalized to untreated samples.  
SARS-CoV-2 was more sensitive to IFN pre-treatment than SARS-CoV in particular in Vero 
E6 cells (Figure 19A and B). 1,000 IU/ml IFN reduced average SARS-CoV-2 replication to 
1.31% ± 1.01% of replication levels in untreated Vero E6 cells, while SARS-CoV replication 
remained unchanged. In Calu-3 cells, pretreatment with 1,000 IU/ml IFN reduced average 
SARS-CoV-2 replication to 0.68% ± 0.11% and SARS-CoV replication to 6.02% ± 4.14% of 
replication levels in untreated control cells.  
Differences were generally less pronounced with IFN applied at 1 hpi (Figure 18C and D), 
pointing to IFN evasion by a virus-encoded antagonist that has to be available in the infected 
cell prior to the start of IFN signaling. 1,000 IU/ml IFN posttreatment reduced average SARS-
CoV-2 replication to 58.26% ± 13.39% and SARS-CoV replication to 17.08% ± 5.61% in Calu-
3 cells. In Vero E6 cells, average SARS-CoV-2 replication was reduced to 11.24% ± 8.49% 




Figure 19. SARS-CoV-2 is more sensitive towards IFN treatment. A and B) IFN pretreatment. Calu-
3 and Vero E6 cells were pretreated with 500 µl of the indicated concentrations of recombinant human 
IFN-β1 18 hours prior to infection with SARS-CoV-2 strain and SARS-CoV at an MOI of 0.001. C and 
D) IFN posttreatment. Calu-3 and Vero E6 cells were posttreated with 500 µl of the indicated 
concentrations of recombinant human IFN-β1 at 1 hpi with SARS-CoV-2 and SARS-CoV at an MOI of 
0.001. Viral titers in the culture supernatant were quantified by plaque titration on Vero E6 cells at 24 
hpi. Average of duplicate infections of four experiments are shown. PFU/ml were normalized to 
untreated samples and plotted as relative PFU/ml. Statistical significance in difference of PFU/ml 
between normalized SARS-CoV-2 and SARS-CoV PFU/ml was determined by Mann-Whitney tests test 







































































l * * *
A B
C D
IFN-β [IU/ml] IFN-β [IU/ml]










































































2.2.2.3 SARS-CoV-2 is less efficient in antagonizing cytokine and IFN-
stimulated gene induction than SARS-CoV 
The differences in IFN sensitivity described in chapter 2.2.2.2 encouraged an investigation 
towards differences in the capacity to antagonize the induction of cytokine expression between 
the two CoVs. SARS-CoV and other CoVs actively antagonize expression of antiviral cytokines 
[86, 144, 147, 221]. Therefore, the mRNA induction of type I IFN and other cytokines were 
investigated in Calu-3 cells infected with two distinct strains of SARS-CoV-2 at early time points 
after infection. The induction of the IRF3-regulated genes IFNB1 and IFNL1, as well as of the 
IRF3- and NF-kB-regulated gene CCL5 was markedly higher following SARS-CoV-2-, as 
compared to SARS-CoV infection (Figure 20A), indicating a less efficient counteraction of 
infection-triggered cytokine induction by SARS-CoV-2.  
In accordance with other reports, IRF3, an activator of IFN gene transcription, was retained in 
the cytoplasm of SARS-CoV-infected cells [120, 222] (Figure 20B). In contrast, upon SARS-
CoV-2 infection, IRF3 readily translocated into the nucleus, suggesting that the mechanism of 
SARS-CoV-mediated retention of IRF3 is not conserved in SARS-CoV-2. Low IRF3 
cytoplasmic retention may explain the higher induction of the IRF3-regulated genes IFNB1 and 
IFNL1 in SARS-CoV-2 infected cells.   
To obtain more insight into the interference of SARS-CoV-2 with IFN-related signal 
transduction, the downstream activation of essential signaling pathways was tested by 
Western blot analysis of infected Calu-3 cells. In accordance with efficient IRF3 translocation, 
phosphorylated IRF3 was readily detected in lysates of SARS-CoV-2-, but not SARS-CoV, or 
uninfected cells (Figure 20C). Lower levels of the NFkB inhibitor, IkBα, were detectable in 
lysates of SARS-CoV-2 infected cells, which is in line with increased CCL5 mRNA induction. 
Probing NFkB in nuclear and cytosolic cell fractions showed more efficient NFkB nuclear 
translocation in cells infected with SARS-CoV-2 than SARS-CoV (Figure 19D). In accordance 
with the increased mRNA induction of the ISGs MX1 and ISG56, STAT1 was more efficiently 
translocated to the nucleus in cells infected with SARS-CoV-2 than SARS-CoV (Figure 19B). 
In line with this result, the IFN-sensitive genes Mx1 and ISG56 were induced more efficiently 





Figure 20. SARS-CoV-2 induces more strongly antiviral signaling pathways than SARS-CoV A) 
quantitative real-time RT-PCR analysis of cytokine mRNA induction in Calu-3 cells infected with two 
strains of SARS-CoV-2 (strain Munich and strain Victoria; BetaCoV/Australia/VIC01/2020; GenBank 
accession number MT007544) and SARS-CoV at MOI = 1. Target gene transcription levels were 
determined at 12 hpi, 16 hpi and 24 hpi and are expressed as fold induction over non-infected control 
cells, normalized to the housekeeping gene TATA-box-binding protein (TBP) using the ΔΔCT method. 
B) IRF3 translocation in SARS-CoV-2 and SARS-CoV infected Calu-3 cells. Cells were infected with 
SARS-CoV-2 and SARS-CoV at MOI = 1, fixed and stained for dsRNA and IRF3 at 16 and 24 hpi IRF3 
signal intensity was measured in ImageJ inside (nuclear) and outside (cytosolic) of the cell nuclei in 
dsRNA positive cells and plotted as a ratio of nuclear to cytosolic signal intensity.  
C and D) Western blot analysis of protein of Calu-3 cells infected with a MOI of 0·5 with SARS-CoV-2 
and SARS-CoV 16 hpi C) Calu-3 whole cell protein lysates were probed for IRF3, phosphorylated IRF3, 
IkBa, cross-reactive SARS-CoV-N and beta actin. D) Calu-3 cell protein lysates were separated using 
the NE-PER kit (Thermo Scientific). Nuclear and cytosolic fractions were probed for NFkB p65, 
STAT1,with GAPDH and Histone H3 as cytosolic and nuclear fraction controls, respectively, and beta 
actin as a loading control. E) q-RT-PCR analysis of Mx1 and ISG56 mRNA induction in Calu-3 cells 


























































































































































































































































2.2.2.4 Availability of the host protease TMPRSS2 is a major driver for 
SARS-CoV-2, but not SARS-CoV replication 
The less efficient counteraction of SARS-CoV-2 against IFN induction does not correspond to 
the initial observation of more efficient growth of SARS-CoV-2 over SARS-CoV in fully IFN-
competent Calu-3 cells. Recent research demonstrated that SARS-CoV-2 makes more 
efficient use of spike protein priming by the transmembrane protease TMPRSS2 than SARS-
CoV [67]. Therefore, the contribution of TMPRSS2 to the replication of both viruses was 
investigated by employing its inhibitor Camostat mesylate in a multi-cycle infection experiment. 
Importantly, Calu-3, but not Vero E6 cells express TMPRSS2 [199]. Pharmacological inhibition 
of TMPRSS2 by Camostat mesylate [67] resulted in a more pronounced reduction of SARS-
CoV-2 infection as compared to SARS-CoV, suggesting that the general growth advantage of 
SARS-CoV-2 in Calu-3 cells might be determined rather by its preferential utilization of 




Figure 21. The TMPRSS2-mediated entry route accounts for higher replication of SARS-CoV-2 
over SARS-CoV in IFN-competent Calu-3 cells. A) replication as determined by plaque titration in 
Vero E6 of SARS-CoV-2 and SARS-CoV in Calu-3 cells 24 hpi (MOI = 0.001) under the influence of 100 
nM of the TMRPSS2 inhibitor Camostat mesylate. B and C) Replication as determined by dsRNA 
staining in fixed Calu-3 cells, 16 hpi with an MOI of 0.01. dsRNA signal intensity quantification was 





2.2.2.4 SARS-CoV-2 protein 6 has reduced function in antagonizing IFN 
signaling  
All results up to this point suggested that SARS-CoV-2 is less efficient than SARS-CoV in 
antagonizing the induction of cytokine genes as well as ISGs, despite the shared genome 
architecture and expression of homologous viral proteins. Among all previously described 
SARS-CoV IFN antagonists (nsp1, nsp3, nsp14, nsp15, nsp16, protein 6, protein 8, protein 9 
and N), protein 6 (encoded by ORF6) shows the highest amino acid sequence divergence 
between SARS-CoV and SARS-CoV-2. SARS-CoV protein 6 binds importin alpha 1 and beta 
1, which are required for STAT1 nuclear translocation, and thereby prevents ISG induction via 
ISRE (IFN-stimulated response elements) promoter elements [147]. To analyze the ISG-
dependent antagonistic function of protein 6 in the context of SARS-CoV infection, 
recombinant SARS-CoV virus mutants in which SARS-CoV ORF6 was replaced with full-length 
ORF6 of SARS-CoV-2 (rSARS-CoVORF6-SARS-2) were constructed by reverse genetics. In brief, 
a SARS-CoV cDNA clone was subjected to mutagenesis via en passant Red-mediated 
recombination, as previously published [223, 224]. Further, ORF6 knockout mutants (rSARS-
CoV ΔORF6), in which the 4th and 5th codon of ORF6 were replaced with stop codons (Figure 
22A), were included in the study. All rescued recombinant viruses were replication-competent. 
In multi-cycle infections in IFN-competent Calu-3 cells (MOI = 0.001), both rSARS-CoVORF6-
SARS-2 and rSARS-CoVΔORF6 replicated more than 10-fold less than wt rSARS-CoV (Figure 
22B). These data confirm that SARS-CoV protein 6 is not essential for replication but enhances 
replication in IFN-competent cells. To confirm that SARS-CoV-2 protein 6 has reduced function 
in antagonizing IFN signaling as compared to SARS-CoV ORF6, single-cycle infection 
experiments (MOI = 1) were performed in Vero E6 cells. Virus replication and viral protein 
expression was allowed for 16 hours, before exposition of cells with type I IFN for 30 minutes 
to mount JAK/STAT-mediated induction of ISGs. Induction of the ISG MX1 whose induction is 
strictly dependent on IFN signaling [225] was tested after 8 hours (Figure 22C). Whereas the 
chimeric virus suppresses MX1 induction to a lesser degree than wild type, induction is 
strongest in cells infected with rSARS-CoV ΔORF6, suggesting that a residual antagonistic 
function is preserved in SARS-CoV-2 ORF6. Intriguingly, the induction phenotype of ISG56 
showed less pronounced differences between rSARS-CoVORF6-SARS-2 and rSARS-CoV ΔORF6. 
The induction of ISG56 is mediated not only by JAK/STAT, but also by IRF3 signaling [226]. 
Therefore, subtle differences in ISG56 induction by JAK/STAT signaling alone may be masked 
by IRF3-mediated ISG56 induction, which is not impeded by the antagonistic functions of 






Figure 22. SARS-CoV and SARS-CoV-2 protein 6 are functional homologues with SARS-CoV-2 
protein 6 displaying reduced capacity in antagonizing IFN signaling. A) left panel: cloning strategy 
of recombinant SARS-CoV ORF6 deletion (rSARS-CoVΔORF6) and SARS-CoV-2 ORF6 chimeric variant 
(rSARS-CoVORF6 SARS-2). B) multi-cycle infections (MOI = 0.001) of rSARS-CoV-wt, -ΔORF6 and -ORF6-
SARS-CoV-2 recombinant viruses in Calu-3 cells. Virus titers were determined at 48 hpi by plaque 
titration on Vero E6 cells. The average of two experiments in duplicates is shown. Statistical significance 
in differences of PFU/ml between rSARS-CoV-wt and -ΔORF6 and -ORF6-SARS-CoV-2 recombinant 
viruses was determined by Mann-Whitney tests test (p-value <0.0332;*; >0.1234; ns). C) IFN pulse 
assay. The outline of the experiment is depicted in the top panel. Vero E6 cells were infected at MOI = 
1. At 16 hpi, cells were treated with the indicated amounts of pan-species type I IFN for 30 minutes. 7.5 
hours later (accounting for 24 hpi in total) cells were lysed and isolated total RNA subjected to 
























































































2.2.3 – Discussion 
The overall results of this study suggest SARS-CoV-2 suppresses cytokine induction as well 
as IFN signaling with lower efficiency than SARS-CoV. Studies employing a SARS-CoV 
reverse genetics clone that expresses SARS-CoV-2 ORF6 implicate that IFN signaling is 
antagonized to a lesser degree in SARS-CoV-2 infection, as function of reduced protein 6 
activity.  
As detailed in chapter 1.6, multiple viral proteins facilitate IFN antagonism in CoVs. Specifically 
for SARS-CoV, nsp3 and nsp1 prevent IRF3 phosphorylation, which is essential for nuclear 
translocation, thereby preventing IFN induction [135, 143, 227]. Nsp1 additionally prevents 
STAT1 phosphorylation upon IFN receptor binding. However, these genes are highly 
conserved between SARS-CoV and SARS-CoV-2. The less conserved protein 6 binds importin 
α1 and β1, thereby preventing STAT1 nuclear translocation and the activation of ISG promoter 
elements [147]. The data of this thesis demonstrate that SARS-CoV-2 protein 6 is less efficient 
in interfering with IFN signaling. A striking difference between SARS- and SARS-CoV-2 protein 
6 is the loss of two charged residues (Q51E and Q56E) at the C-terminal domain, which has 
been shown to be essential for importin binding [147]. Loss of charge in SARS-CoV-2 protein 
6 may reduce the capacity to interact with importins and warrants for further clarification by 
pulldown studies with tagged protein 6. These studies might help to address the question if 
SARS-CoV-2 protein 6 interacts with the same importins as SARS-CoV and if importin binding 
is conserved among different host species. As SARS-CoV-2 evolution is likely to take place in 
bats [46, 52], protein 6 might have undergone functional adaptation in binding to bat importins.  
Under the impression of an ongoing SARS-CoV-2 pandemic, reduced antagonistic capacity of 
SARS-CoV-2 protein 6 in human cells conveys a warning to the course of the pandemic. As 
protein 6 of both SARS- and SARS-CoV-2 are structurally homologous and seem to evade 
IFN signaling via the same mechanism of action, the function of SARS-CoV-2 protein 6 may 
undergo adaptive evolution in humans. As the intense circulation of SARS-CoV-2 in the human 
population continues, potential increases of anti-IFN functions, as mediated by protein 6, may 
trigger increases of replication level that are ultimately selected for in virus evolution. As virus 
transmission continues, sequence-based surveillance combined with experimental 
assessment of phenotypic change should involve studies of ORF6 and other presumed IFN 
antagonists and monitor for possible changes in IFN signaling antagonism.   
A recently published study compiled further evidence that both SARS- and SARS-CoV-2 
protein 6 are IFN antagonists [146]. Intriguingly, the authors did not detect a reduced 
antagonistic capacity of SARS-CoV-2 protein 6. The authors further claim an additional 
antagonism of IRF3-mediated type I IFN induction by protein 6, which is not in line with data 
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obtained from wild-type SARS-CoV-2 infection (Figure 20) and could not be detected in 
rSARS-CoVORF6 SARS-2 infection. However, there is a key difference in the applied methodology 
between the two studies. While Yuen et al. conducted promotor activation assays based on 
overexpression of protein 6, we investigated the effects of endogenous protein 6 in the context 
of virus replication. Unfortunately, the authors did not detail their exact methodology, e.g. which 
(and if the identical) expression vector backbones were used for each construct, or how much 
plasmid was transfected, which are key determinants for the outcome of promotor activation 
assays. Furthermore, results based on overexpression of single viral proteins suffer from 
systemic pitfalls, as they do not reflect endogenous protein levels in the context of virus 
infection and cannot account for interactions between several viral proteins.  
A tempting extrapolation of the in vitro data presented here towards in vivo clinical presentation 
is that the less efficient innate immune evasion by SARS-CoV-2 correlates with the less severe 
clinical manifestation of COVID-19 over SARS. Increased cytokine and ISG induction by 
SARS-CoV-2 may enable quick virus clearance and halt disease progression in patients with 
a largely functional immune system. Intriguingly, a recently published study employed single 
cell sequencing on SARS-CoV-2 infected ex vivo lung explants and found SARS-CoV-2 to not 
induce significant amounts of IFNs, juxtaposed to increased NF-kB-mediated genes, as 
observed here [228]. Contrasting to that, a single cell study performed by members of our 
institute observed a similar phenotype of SARS-CoV-2-mediated IFN mRNA upregulation, as 
observed here [229]. It should be added that the host response may vary as a function of 
applied MOI, of the timing of mRNA quantification, of the model system used for infection and 
possibly as a function of virus isolate used for infection. Consequently, extrapolations towards 
any clinical phenotype have be confirmed by more data to clarify SARS-CoV-2 IFN evasion 
and antagonism, particularly in ex vivo systems.           
Functional diversity in protein 6 and other accessory proteins may help to elucidate the 
zoonotic potential emanating from Coronaviridae. Previous studies have shed some light on 
the functional diversity of protein 8 [230] and nsp3 [227] in SARS-CoV, and protein 4b in 
MERS-CoV [176] and the data for protein 6 provided here add to that line of thought. Functional 
differences in the ability to counteract innate immunity seems to appear as a marker for 
pathogenicity of CoVs. The suppression of innate immunity, whose protein components are 
largely conserved among mammals, may help to explain why CoVs seem to be able to 
overcome species barriers so frequently. Considering SARS-CoV and SARS-CoV-2 as 
conspecific viruses with an overall homologous genome structure and receptor usage [52, 66, 
67] the results presented here highlight that functional diversity may exist in members of closely 




In sum, the results of both parts of the thesis at hand underline the urgency to intensify CoVs 
surveillance. Particularly in their animal reservoirs where diversity is largest, surveillance 
should be extended from purely sequence- and phylogeny-informed research towards 
phenotypical studies, as functional diversity seems to be present among closely related CoV 
species. The identification of causal networks between CoV genomic loci and their 
phenotypical traits might help to identify risk markers for CoV virulence and provide a better 




3 – Methods 
 
3.1 - General cell culture procedures 
MERS-CoV plaque titrations (chapter 3.6) and virus stock production (chapter 3.2) were 
conducted using Vero B4 cells. For SARS-CoV and SARS-Cov-2 Vero E6 cells were used. In 
virus infection studies (chapter 3.4), Vero B4, Vero E6, Calu-3, Caco-2, Huh-7, T84 wild-type 
and T84 IFN alpha and lambda receptor double knockout cells were used. For the production 
of MERS-CoV spike protein-pseudotyped VSV particles, HEK-293T cells were used (chapter 
3.17). All cells were maintained at 37°C, 5% CO2 in Dulbecco’s Modified Eagles Medium 
(DMEM), high glucose (4.5 g/L) supplemented with 5% Penicillin/Streptomycin, 5% non-
essential amino acids, 5% sodium pyruvate, 5% L-glutamine and 10% FCS (lot number 
2058470) (all Gibco). For freshly thawed Calu-3 cells, FCS supplement was increased to 20% 
for two passages. Culture vessels for T84 cells were coated with type I collagen for 1 hour prior 
to seeding. Passaging of cells was performed when cells reached a confluency of 80% or 
higher, in a 1:10 ratio for all cells, expect for Calu-3 and T84 cells, which were passaged in a 
1:3 ratio. For passaging, cells were washed with twice with PBS and exposed to 0.25% Trypsin 
solution until cell detachment was completed. Detached cells were counted in a Neubauer 
chamber and diluted to the appropriate concentration (chapter 3.4) prior to cell seeding.  
3.2 - MERS-CoV isolate stock production 
Generation of primary MERS-CoVs isolates from anonymous patient respiratory samples was 
performed by Doreen Muth in late 2015 [187]. In brief, qRT-PCR positive samples were diluted 
in OptiPro to reduce mucous viscosity and subsequently used to infect Caco-2 and Vero B4 
cells, seeded in a 6-well format. Infections were performed as described in chapter 3.4. Cells 
were monitored daily and at the onset of CPE the culture supernatant was collected and stored 
at -80°C for working stock generation.   
For MERS-CoV working stock production, Vero B4 cells seeded in a T162 flask format were 
infected with primary MERS-CoV isolates. To avoid carry-over of potential fungus 
contaminations, frequently observed in primary isolates from respiratory samples, inocula were 
passed through a 0.22 µm filter prior to inoculation. In addition, Amphotericin B was 
supplemented in the culture medium at a concentration of 1 µg/ml. Infected Vero B4 cells were 
incubated at 37°C, 5% CO2 and monitored daily for CPE. Once complete CPE was observed 
after approximately 3-4 days, the culture supernatant was collected and centrifuged at 4,000 
rpm for 30 minutes to remove cellular debris. Debris-free supernatants were collected and 
concentrated using Vivaspin 20 ml concentrator columns. In brief, supernatants were loaded 
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onto PBS equilibrated columns and centrifuged at 4,000 rpm at 4°C for 1 hour. The remaining 
volume was collected from the column filters by washing with 10 ml PBS. The resulting high 
titer virus solution was mixed in a 1:2 ratio with 0.5% gelatin-containing OptiPro medium and 
aliquots of 500 µl were stored at -80°C. 
3.3 - IFN, Ruxolitinib and Camostat mesylate treatment 
Prior to infection, Vero E6 (SARS and SARS-CoV-2) and Calu-3 cells (the former, plus MERS-
CoV) were incubated with 500 µl of the indicated human IFN-β (Biochrom, Germany) or pan-
species type I IFN (PBL Biomedical Laboratories) concentrations, diluted in culture medium, 
for 18 hours (chapter 2.1.2.12 and 2.2.2.2). For IFN posttreatment, culture medium was 
changed to full DMEM supplemented with the indicated concentrations of IFN-β one hour after 
infection. For IFN pulse experiments (chapter 2.2.2.4), pan-species type I IFN was diluted in 
culture medium at the indicated concentrations. At 16 hpi, the culture medium was replaced 
with IFN-supplemented culture medium for 30 minutes. Subsequently, IFN-containing medium 
was removed and composite DMEM without IFN was added to the cells.  
Camostat mesylate (Sigma-Aldrich) and Ruxolitinib (Invivogen) treatment (chapter 2.1.2.8 and 
2.2.2.4) was performed by supplementing complete DMEM with 100 µM Camostat mesylate 
or 100 nM Ruxolitinib, or DMSO (as a control for Ruxolitinib treated cells) and by pretreating 
Calu-3 cells 2 hours prior to infection. After infection, cells were maintained in Camostat 
Mesylate-, Ruxolitinib-, or DMSO-supplemented DMEM.  
3.4 - MERS-, SARS- and SARS-CoV-2 infections 
Detached cells were counted and seeded 16 hours prior to infection studies. Seeding densities 
were used as detailed below. 500 µl and 2,000 µl culture medium were used for 24-well and 
6-well cultures, respectively. 
 
Seeding density (cells/well): 
Cell line: 24-well: 6-well: 
Calu-3  3.0x10e5 1.2x10e6 
Caco-2  1.5x10e5 Not applicable 
T84 (wild-type and KO) 2.5x10e5 Not applicable 
Vero (B4 and E6) 1.5x10e5 6.0x10e5 
 
Virus stocks were thawed and diluted in OptiPro (Gibco) to the desired MOI (e.g. 500 PFU for 
2.5e5 Calu-3 cells to reach an MOI of 0.002). Culture medium was removed and the cells were 
washed once with PBS, prior to inoculation with virus dilutions for 1 hour at 37°C. Following 
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incubation, cells were washed twice with PBS and 500 µl (24-well format) or 2 ml (6-well 
format) culture medium was added to each well. Infected cells were further incubated at 37°C.  
All experiments with MERS-CoV, SARS-CoV-2 and SARS-CoV were executed under BSL-3 
conditions.  
3.5 - Synchronized MERS-CoV infections 
To investigate early steps in virus infections, virus attachment to host cells was performed at 
low temperatures, at which the energy barrier for efficient host cell fusion and cell entry is high 
[231]. After an particle attachment incubation period at 4°C, the temperature was rapidly shifted 
to 37°C to allow for synchronized virus entry into the cells (chapter 2.1.2.8 and 2.1.2.10).  
Virus stocks were thawed and diluted in 4°C cold OptiPro to the desired MOI. Calu-3 and Vero 
B4 cells, seeded in 24-well format, were kept on ice, the culture medium was removed and the 
cells were washed once with cold PBS. After the addition of virus dilutions, the cells were 
incubated at 4°C for 1 hour and subsequently shifted to 37°C for 30 minutes. Cells were 
washed five times with PBS and 500 ml culture medium was added to each well. Further 
incubation was carried out at 37°C.  
3.6 - Plaque titration assay  
The amount of infectious particles in a virus containing dilution can be quantified by the plaque 
assay technique [232]. This technique applies the principle that virus progeny of a single 
infected cell can only infect immediately neighboring cells when the cell monolayer is overlaid 
with a viscous medium. Consequently, each infectious particle forms a so-called plaque, a 
hole, in the cell monolayer. The number of formed plaques positively reflects the amount of 
PFU present in the dilution used to infect the cell monolayer.  
Samples with unknown virus concentration were 10-fold serially diluted and applied to Vero B4 
or E6 cells (1.5e5 cells/well) in duplicates. After a 1-hour incubation period at 37°C, sample 
dilutions were removed and overlaid with a 1:2 solution of 2.4% Avicel (Sigma-Aldrich) and 
double-concentrated DMEM (Gibco). Four days post infection cells were washed once with 
PBS and fixed in 6% formaldehyde solution for 30 minutes. The cell monolayer was stained by 
adding a 6% formaldehyde solution containing crystal violet for 15 minutes. Stained and fixed 
plates were washed twice with water, dried at room temperature. Formed plaques were 
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3.7 - Primary human airway epithelium infection and culture procedures 
Prof. Dr. Ronald Dijkman, Institute for Virology and Immunology, at the University of Bern, 
provided fully differentiated primary human airway epithelia (HAE). HAE cells were seeded on 
transwell inserts that allow cells to be supplied by medium from the apical (top) and basolateral 
(bottom) side. After reaching confluency and establishing a tight junction barrier (monitored by 
measuring the electrical resistance between apical and basolateral compartment), apical 
medium was removed to drive differentiation of HAEs by exposure to air on the apical site 
(creating an air-liquid-interface (ALI) culture). HAEs were fully differentiated in Bern and 
shipped to Berlin with an agarose overlay. Upon arrival, the agarose overlay was removed, 
and the inserts washed twice with HBSS (Gibco) to remove excess agarose. HAEs were further 
incubated for one week prior to infection, to allow the cells to recover from the shipment. ALI 
medium (produced in house by R. Dijkman) was exchanged from the basolateral site every 
second day [233].  
For infection with MERS-CoV (chapter 2.1.2.14) HAEs were washed twice with HBSS to 
remove excess mucous and infected with 4,000 PFU diluted in HBSS for 1.5 hours. 
Subsequently, cells were washed three times with HBSS and further incubated. At 24, 48, 72 
and 96 hpi supernatants were collected from the apical site. Viral loads were quantified by 
plaque titration on Vero B4 cells as described in chapter 3.6. 
3.8 - Lung explants infection and culture procedures 
Lung explant infections with selected MERS-CoV isolates were performed in cooperation with 
Christin Mache under Thorsten Wolff´s supervision at the Robert Koch Institute, Unit 17, 
Influenza and other Respiratory Viruses, in Berlin, Germany.  
Lung explants were obtained from patients undergoing lung resection. Written informed 
consent was obtained from all patients and the study was approved by the ethics committee 
at Charité- Universitätsmedizin Berlin (projects EA2/050/08 andEA2/023/07). For each 
experiment tumor-free, human lung tissue was cut into small pieces (weight approx. 0.1 - 0.2 
mg per piece) and incubated in RPMI 1640 (Gibco) medium at 37°C with 5% CO2. After 
overnight incubation, lung organ cultures were inoculated with 1x10e5 PFU MERS-CoV for 1.5 
hours, washed once with PBS and further incubated on a tissue culture shaker with 50 rpm 
(chapter 2.1.2.14). Lung tissue was incubated for up to 72 hpi in RPMI 1640 medium containing 
10% FCS and 2 mM L-glutamine (both Gibco). Supernatants of infected lung tissue were 
collected at 0, 16, 24, 48 and 72 hpi and were titrated on Vero B4 cells by plaque titration assay 
as described in chapter 3.6.  
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3.9 - Plaque Reduction Neutralization Test (PRNT) 
The plaque reduction neutralization test (PRNT) quantifies virus-specific neutralizing 
antibodies. The technique is based on the assumption that viruses do not form plaques when 
specific antibodies neutralize them. Serial dilutions of five serum samples (Table 1 chapter 
2.1.2.19), containing antibodies against MERS-CoV were incubated for 1 hour with 25 PFU 
prior to performing a plaque assay as described in chapter 3.6. After fixation and staining, as 
described in chapter 3.6, plaques were counted and the reduction of plaques in samples pre-
incubated with serum dilutions was calculated. The standard measure for neutralization 
capacity is given as the PRNT50, i.e. the serum dilution step at which half of the 25 input PFUs 
are neutralized. 
3.10 - Virus competition assay 
Calu-3 cells were infected in 24-well format with a mixture of two MERS-CoV strains, using 
two ratios (1:1 and 9:1) (chapter 2.1.2.6). The total infectious dose used to infect passage 0 
cultures was set to 10,000 PFU, corresponding to an MOI = 0.04. All passaging infections were 
performed by sampling the supernatant of the previous passage at 24 hpi and inoculating a 
new Calu-3 culture with a 1:50 dilution of that sample. This process was repeated until the 
completion of five passages. Viral RNA was isolated from the initial inoculum (p0) and from the 
supernatant after five passages (p5) and subjected to Sanger sequencing of three different 
single nucleotide polymorphisms (SNP) sites that were each amplified from the virus 
population in separate RT-PCR reactions to control for PCR-based artifacts. The following 
PCR products were generated: amplicon 1 (300 bp): forward primer: 5´-
TACCTGGTTGAGAGGCTCAT-3´; reverse primer 5´-CTTAAGCAGATTCTGGGCATATT-3´; 
amplicon 2 (541 bp): forward primer 5´-TGAGTGTGGAAGTTGTGGTAAT-3´; reverse primer 
5´-ACCTTTGAGAAGCTGGCGTATT-3´; amplicon 3 (560 bp): forward primer 5´-
TCGAGCCGCATAAGGTTCAT-3´; reverse primer 5´-GCTGAGCTGCGTCCTGTTT-3´. For 
peak height analysis, the web based Chromat Quanitator (Mullins lab, University of 
Washington, chapter 4.12) was used and obtained peak heights were averaged for all 
duplicates and calculated as a percent of the total height. 
3.11 - Deep sequencing of MERS-CoV virus stocks 
3 µg viral RNA, extracted from high titer MERS-CoV stocks (passage 2) as described in chapter 
3.2 and 3.21, was subjected to cDNA synthesis using the SuperScript® One-Cycle cDNA Kit 
(Invitrogen) according to the manufacturer's protocol. 1 ng cDNA was fragmented and 
supplemented with adapter sequences using the Nextera® XT DNA Library Prep (Illumina), 
subsequently processed with the MiSeq Reagent Kit v3 (Illumina) and subjected to NGS on a 
MiSeq™ System (Illumina), all according to the manufacturer’s protocol. 
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3.12 - Sequence assembly of NGS reads 
Using the Geneious software, version 9.1.8, NGS reads were trimmed and mapped to the EMC 
MERS-CoV reference genome (accession number JX869059). Reads shorter than 50 bp were 
excluded from the mapping. Trimming of reads was set to 5%. The threshold for generation of 
the consensus sequence of all reads was initially set to 90%. Each obtained consensus 
sequence was manually screened for ambiguous nucleotides. If ambiguous nucleotides were 
identified, the consensus sequence threshold was lowered to 75%. Sequences that did not 
yield unambiguous consensus sequences at 75% reads were excluded from further studies 
(chapter 2.1.2.2).  
3.13 - Phylogenetic analysis of MERS-CoV genome sequences  
Phylogenic analyses were estimated applying a Maximum-likelihood approach, implemented 
in RaxML, version 8.0.0, with a general time reversible (GTR) model of nucleotide substitution 
with 4 category gamma distributed rate variation and a proportion of invariant sites. 10,000 
bootstrap replicates were set. No further changes to the default settings of RaxML were 
applied. Calculation were performed on the BIH server cluster, to allow for the replicates to be 
calculated in a reasonable time scale. Input alignments for all trees were created by ClustalW, 
implemented in the Geneious software, version 9.1.8. Calculated trees were edited for better 
graphical display, using FigTree v1.4.4 (chapter 2.1.2.4).  
3.14 - In-depth recombination analysis 
For detailed recombination analysis, we performed a BootScan analysis with 500 bootstraps 
in SimPlot, version 3.5.1., with a sliding window of 5,000 bp and 200 bp steps. An alignment 
of four sequences, comprising phylogenetic clade A (EMC-2012) and three clade B lineages,  
lineages 3, 4 and 5 (Riyadh-146 2014, Jeddah 2014 10306 and Riyadh 2015-1734) was used 
for the BootsScan analysis, with Riyadh 2015-1734, the suspected recombinant, set as query 




3.15 - Cloning of MERS-CoV lineage-specific spike gene expression 
vector by mutagenesis PCR 
For the generation of lineage-specific spike gene expression vectors, the previously cloned 
EMC-2012 isolate spike plasmid (pCG1-MERS-S) was used as a template for site-directed 
mutagenesis PCR. Lineage-specific nucleotide changes were introduced into the EMC spike 
plasmid by a set of specific primers, listed in chapter 4.8.3. Phosphorylated primers were used 
to allow for efficient ligation of the circular PCR product. The reaction as set up as a two-mix, 
hotstart PCR, using Phusion polymerase as described below: 
Mix 1: 
H2O 27.5 µl 
HF buffer (5x) 7.5 µl 
dNTPs 2 µl 
Primer Fwd 1 µl 
Primer Rev  1 µl 
Template (10 ng) 1 µl 
Total volume: 40 µl 
 
Mix 2: 
H2O 7 µl 
HF buffer (5x) 2.5 µl 
Phusion Polymerase  0.5 µl 
Total volume: 10 µl 
 
The reaction was conducted in a PCR cycler with the following cycling conditions: 
Add Mix 1 template denaturation 98°C 30 sec 1x 
 template denaturation 80°C 1 min 
Add Mix 2 Denaturation 98°C 10 sec 
35x  Primer annealing 66°C 20 sec 
 Extension 72°C 200 sec 
 Final Extension 72°C 10 min 1x 
 4°C Storage ∞  
 
Amplification of DNA was verified by agarose gel electrophoresis. Successful amplicons were 
subjected to background template digestion employing 2 µl Dpn1 restriction enzyme (NEB) in 
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50 µl total volume with 1x CutSmart buffer (NEB) at 37°C for 20 minutes. Subsequently, 
amplicons were column purified (Machery&Nagel) and 5 µl PCR product was ligated at room 
temperature using 1µl T4 Rapid enzyme (Thermo Scientific) in 1x RapidLigation buffer 
(Thermo Scientific) in a total volume of 10 µl for 30 minutes. Subsequently 3µl ligation product 
were used to transform E. coli One Shot Top10 bacteria (Thermo Scientific) as described in 
chapter 3.25.  
Initially the mutation Q1020R was introduced into the EMC backbone and the obtained plasmid 
DNA was isolated from transformed bacteria using the Machery&Nagel Plasmid Purification 
Kit (chapter 3.16). The mutagenesis reaction was verified by Sanger sequencing, and the 
isolated plasmid subsequently used as a as PCR template for the subsequent introduction of 
L411F and Q833R by a second round of mutagenesis PCR as described above. In total, three 
MERS-CoV spike gene plasmids were generated: L411F and Q1020R in combination, Q833R 
and Q1020R in combination, as well as Q1020R alone (chapter 4.9). All plasmids were isolated 
and purified as described in chapter 3.16.   
3.16 - Isolation of plasmid DNA  
For small scale DNA purification, the Machery&Nagel Plasmid purification kit was used. For 
large-scale DNA purification the Machery&Nagel Extra Midi EF kit was used, both according 
to the manufacturer´s instructions. For small-scale DNA isolation, a single bacterial colony was 
inoculated in 5 ml LB broth supplemented with the required antibiotic. For large-scale DNA 
isolation, an overnight small-scale bacterial culture of a single bacterial colony was inoculated 
in 300 ml LB broth supplemented with the required antibiotic. Elution of purified plasmids was 
performed with 50 µl and 200 µl 50°C Tris-HCl buffer, pH 8, for small-scale and large-scale 
DNA purification, respectively.  
3.17 - Generation of MERS-CoV spike protein-pseudotyped VSV 
particles (VSVpp) and virus transduction studies 
Cell entry capacity of MERS-CoV-S proteins can be quantified by the VSVpp system [234, 
235]. The system is based on a recombinant Vesicular Stomatitis Virus (rVSV) in which the 
gene mediating cell entry, VSV-G, was replaced by genes encoding for eGFP and firefly 
luciferase (fLuc). rVSV particles can be trans-supplemented with overexpressed viral 
glycoproteins, including MERS-CoV-S. These trans-supplemented MERS-CoV-S VSVpp can 
be used to infect MERS-CoV susceptible cell lines. MERS-CoV-S- VSVpp transduces infected 
cells with the eGFP and fLuc genes, than can subsequently be quantified.   
In brief, 293T cells seeded in 6-well format were transfected with 6 µg pCG1 expression vectors 
(chapter 4.9) carrying MERS-CoV spike protein variants produced as by mutagenesis PCR as 
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described in chapter 3.15) [183], and VSV-G (positive control) or empty pCG1 expression 
vector (negative control). 16 hours post transfection, the 293T cells were inoculated with 1 ml 
VSV*ΔG-fLuc diluted in OptiPro at an MOI = 3 at 37°C for 1 hour, washed twice with 1 ml cold 
PBS and further incubated at 37°C with 2 ml culture medium, supplemented with 1:1,000 anti-
VSV-G antibody (except for cells expressing VSV-G). After 16-18 hours incubation, 2 ml of the 
VSVpp containing culture supernatant was collected and the cell debris removed by 
centrifugation (4,000 rpm, 4°C, 10 min). Aliquots of 250 µl were stored at -80°C.   
For transduction of target cells, Calu-3, Caco-2 and Huh-7 cells were seeded into 96-well cell 
culture plates for 16 hours, the culture medium was removed and cells were inoculated with 
100 µl MERS-CoV-S VSVpp. At 18 hours postinoculation cells were lysed for 15 minutes at 
room temperature in 50 µl Luciferase Cell Culture Lysis Reagent (Promega). Lysates were 
diluted 1:10 in water and 20 µl were transferred into white, opaque-walled 96-well plates and 
activity of virus-encoded fluc was measured using 50 µl of the Luciferase Assay System 
substrate (Promega) and a Hidex Sense plate reader (Hidex). 
3.18 - Quantification of MERS-S binding to DPP4 by flow cytometry 
Analysis of spike protein binding to the host receptor DPP4 was analyzed by flow cytometry 
employing a previously published protocol and was performed by Hannah Kleine-Weber at the 
German Primate Center (DPZ) in Göttingen [183]. In brief, 293T cells were transfected with 
the overexpression vector pCG1 carrying the MERS-CoV Spike protein of clade A (EMC, 
accession number JX869059), lineage 3 (L411F/Q1020R), lineage 4 (Q833R/Q1020R), or 
lineage 5 (Q1020R), as well as empty vector for negative control. At 48 hours post transfection, 
cells were resuspended in PBS, centrifuged (5 minutes at 600x g at 4 °C) and resuspended in 
PBS containing 1% bovine serum albumin (1% BSA/PBS) for washing. The cells were 
centrifuged again and incubated in 1% BSA/PBS containing soluble DPP4 equipped with a C-
terminal human Fc-tag (solDPP4-Fc,1:50, 1:200 and 1:1,000; ACROBiosystems) at 4 °C in an 
overhead shaker for 1 hour. Afterwards, the cells were pelleted and incubated in 1% BSA/PBS 
containing an AlexaFluor488-conjugated anti-human antibody (1:500), for 1 hour at 4 °C in an 
overhead shaker. Subsequently the cells were pelleted, washed with 1% BSA/PBS and fixed 
in 4% paraformaldehyde (PFA) solution for 20 minutes at room temperature. Prior to analysis 
via flow cytometry, the cells were pelleted again and washed with 1% BSA/PBS. Flow 
cytometry was conducted on an LSR II Flow Cytometer (BD Bioscience). Data was further 
processed in the FCS Express 4 Flow research software (De Novo software). Assessment of 
entry and DDP4-binding capacity of pseudotyped VSV particles was performed in collaboration 




3.19 - IRF3 translocation assays 
1.5e5 Calu-3 cells were seeded in 8-well µ-slides (80826, ibidi) and infected with SARS-CoV 
FFM-1 or SARS-CoV-2 Munich 984 at the indicated MOI. 16 or 24 hpi, cells were fixed in 6% 
PFA, permeabilized in 0.1% Triton-X and blocked with 2% BSA in PBS. Antibody-staining was 
performed with a 50 µl dilution of mouse anti-dsRNA (J2, English and Scientific Consulting, 
Hungary, 1:200) and rabbit anti-IRF3 (FL-425, sc-9028, Santa Cruz Biotechnology, 1:200) in 
PBS, 2% BSA for 2 hours. For secondary staining, 50 µl of a goat anti-mouse Alexa Fluor-647 
(A-21235, Thermo Fisher Scientific, 1:300 with 1:1000 Dapi solution (Thermo)) dilution and a 
goat anti-rabbit Alexa Fluor-488 (A-11008, Thermo Fisher Scientific, 1:300) dilution were 
applied for 1 hour. Cells were washed three times in PBS following blocking, as well as primary 
and secondary antibody incubation. Imaging was performed using the Zeiss LSM800 Airyscan 
confocal microscope. Signal intensities were analyzed using ImageJ 2. 
3.20 - Western blot analysis 
Calu-3 cells were lysed in Pierce RIPA lysis buffer (Thermo Scientific) supplemented with 
PhosStop (Roche) and complete Protease Inhibitor mix (Roche) at 16 hpi. For nuclear and 
cytosolic fraction analysis, protein lysates were separated using the NE-PER kit, according to 
the manufacturer´s instructions (Thermo Scientific). Cell lysates were resolved on 14% SDS-
PAGE gels and blotted onto nitrocellulose membranes using a Trans-Blot Turbo system 
(BioRad). Subsequently, membranes were blocked with 5% milk powder in TBS with 0.05% 
Tween-20 (TBST) for 1 hour, prior to overnight incubation at 4°C with the respective primary 
antibodies, diluted 1:1,000 in TBST, 5% milk powder as follows: p-IRF3 (cs#4947s); IRF3 
(cs#4302s); IκBα (cs#4812s); SARS-CoV-N (GTX632269); ß-Actin (Sigma A5316); NFkB p65 
(cs#6956s); STAT-1 (cs#9172); GAPDH (cs#5174s) and Histone H3 Sigma (H0164). After 
overnight incubation, membranes were washed with TBST and probed with secondary HRP-
conjugated antibodies (Thermo Scientific), diluted 1:20,000 in TBST, 5% milk powder, for 1 
hour at room temperature. Protein band visualization by autoradiography was performed by 
addition of SuperSignal West Pico Plus (Thermo Scientific) chemiluminescence substrate.   
3.21 - Manual isolation of viral RNA 
Viral RNA was isolated from culture supernatants of infected cells using the Machery&Nagel 
viral RNA kit according to the manufacturer´s instructions. 50 µl of cell culture supernatant 
were added to 300 µl RAV1 lysis buffer, supplemented with carrier RNA. Samples were either 
stored at -80°C or processed immediately. Virus containing RAV1 samples were heat-
inactivated for 10 minutes at 70°C, before being exported from the BSL-3. RNA was eluted in 
50 µl H2O and stored at -80°C.  
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3.20 - Manual isolation of total cellular RNA 
At the respective time point post infection, cell culture supernatant was removed and the cells 
were lysed in 350 µl RA1 buffer, supplemented with 2-mercaptoethanol. Samples were either 
stored at -80°C or processed immediately. Virus-containing RAV1 samples were incubated for 
10 minutes at 70°C before being exported from the BSL-3. RNA was isolated using the 
Machery&Nagel total RNA kit according to the manufacturer´s instructions. RNA was eluted in 
50 µl H2O and stored at -80°C.  
3.21 - Automated isolation of viral RNA 
Large-scale cellular RNA isolations were performed on an automated nucleic acid isolation 
extraction platform (MagNAPure (Roche)). In brief, cells were lysed in 350 µl MagNA Pure cell 
lysis buffer, transferred to Eppendorf tubes and either stored at -80°C or processed 
immediately. Lysed samples were incubated for 10 minutes at 70°C, before being exported 
from the BSL-3. After BSL-3 export, 300 µl of each samples were transferred to 96 deep-well 
plates and the nucleic acid isolation was performed using the small volume nucleic acid kit 
(Roche), and following the manufacturer’s preset protocol for blood samples. Elution was done 
in 100 µl H2O and the eluate was stored at -80°C.  
3.22 - Purification of PCR products  
PCR products intended for cloning or sequencing were UV visualized after electrophoresis on 
1% agarose gels to check for the presence of unspecific PCR byproducts. PCR products that 
displayed no unspecific PCR products were purified using the Machery&Nagel NucleoSpin Gel 
and PCR clean-up system, according to the manufacturer´s protocol. PCR products with 
unspecific products and PCR products obtained from plasmid templates were separated from 
unspecific products by low voltage (70V) 1% agarose TAE gel electrophoresis, excised with a 
disposable scalpel and subsequently subjected to purification using the Machery&Nagel 
NucleoSpin Gel and PCR clean-up system, according to the manufacturer´s protocol. Exised 
agarose gel pieces were incubated with 400 µl NTI buffer at 50°C and 1,000 rpm for 10 
minutes. 
3.23 - Photometric quantification of nucleic acid concentration  
A NanoDrop 1000 (Thermo Fisher Scientific) spectrophotometer was used for nucleic acid 
concentration measurements, blanked with the same solvent that nucleic acids were 




3.24 - Bacterial transformation, colony PCR and glycerol stock 
production  
Ligation reactions were transformed into 50 µl chemically competent TOP10 (Invitrogen) or 
NEB 10-beta E. coli (NEB) according to manufacturer’s protocol. In brief, 50 µl of TOP10 or 
NEB 10-beta E. coli cells were thawed on ice. 5 µl ligation reaction was incubated on ice for 
20 minutes, subjected to a heat shock at 42°C for 30 seconds, placed on ice for another 2 
minutes before recovery in 250 µl SOC medium (NEB) at 37°C 300 rpm for 1 hour. 300 µl 
transformed bacterial cells were in SOC medium were spread out in on LB agar plates 
containing the respective selection antibiotic (30 µg/ml Kanamycin, 50 µg/ml Carbenicillin, or 
10 µg/ml Chloramphenicol, all from Thermo Scientific) and incubated overnight at 37°C or for 
two days at 32°C.  
Single bacterial colonies resuspended in 15 µl H2O were used as a template for colony PCR 
using Taq Polymerase (Thermo Scientific) according to manufacturer´s protocol. For 
mutagenesis PCR control, a set of primers was used that generates a 500 bp PCR amplicon, 
which comprises the respective area of mutagenesis. For each mutated region (L411F, Q833R 
and Q1020R), four PCR reactions with four individual colonies were sent for Sanger 
sequencing to distinguish mutagenesis and background template constructs. Confirmed 
positive colonies were inoculated in 200 ml LB medium, supplemented with the respective 
selection antibiotic, and incubated at 37°C, 300 rpm for 14-16 hours. Saturated LB medium 
cultures were subjected to plasmid preparation as described in chapter 3.16. In addition, 500 
µl of the bacterial culture was mixed with 500 µl of 50% glycerol in water and stored at -80°C 
for long-term storage.   
3.25 - Sanger Sequencing 
Sanger sequencing of purified PCR products was outsourced to MicroSynth Seqab in 
Göttingen. Sequencing primers (500 nM final concentration) and PCR products were provided 
according to the company´s recommendations, with 40-100 ng/µl final plasmid concentration 
and 4-30 ng/µl final PCR product concentration in 12 µl total volume. Ab1 files with obtained 
sequencing reads were mapped to their respective template in Geneious v9.1.8.  
3.26 - Quantitative real-time PCR (q-RT-PCR) 
Quantitative real time RT-PCR analysis was to quantify viral RNA in the cell culture 
supernatants of infected cells, or to quantify transcriptional regulation of cellular mRNAs. For 
quantification of viral RNA, 50 µl cell culture supernatant were isolated using the 
Machery&Nagel viral RNA kit (chapter 3.21). For quantification of cellular mRNAs, total RNA 
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of virus-infected cells was isolated using either Machery&Nagel total RNA kit, or by using the 
automated MagNAPure platform (chapter 3.21).  
For host mRNA quantification, a two-step PCR protocol was used. First, cDNA was prepared 
from 5 µl of a 100 ng/µl viral RNA dilution using the iScript™ cDNA synthesis kit (Bio-Rad), 
according to the manufacturer's protocol. Second, cDNA was amplified and quantified using 
Taq-polymerase (Invitrogen) and a set of real time primer and probes for each transcript under 
investigation (chapter 4.8.4). For quantification of sgmRNA N and genomic ORF1a transcripts, 
cells were lysed at 0, 2, 4, 6, 8, 10, 12 and 24 hpi. Total RNA was isolated and subjected to 
quantitative real-time PCR using the one-step SuperScript III kit (Invitrogen) according to the 
manufacturer´s protocol. PCR cycler conditions were set as follows: a single cycle of 20 
minutes at 55°C and 3 minutes at 98°C, followed by 40 cycles of 15 seconds at 98°C and 30 
seconds at 58°C.  
3.27 - Cloning of recombinant rSARS-CoVORF6-SARS-CoV-2 and rSARS-
CoVΔORF6 cDNA constructs by red-mediated recombination 
SARS-CoV carrying SARS-CoV-2 ORF6 (rSARS-CoVORF6-SARS-CoV-2) and the ORF6 deletion 
virus (rSARS-CoVΔORF6) were constructed from a rSARS-CoV cDNA clone [224] by red-
mediated recombination [223, 236]. The transfer constructs required for recombination and 
selection were generated as follows: For the generation of the ORF6 deletion transfer cassette, 
the I-SceI-aphAI transfer cassette was amplified, containing 5´and 3´ 37 bp homologous hooks 
to the SARS-CoV genome with the forward primer 5´- 
GCTTTGCTAGTACAGTAAGTGACAACAGATGTTTCATTAATAGGGATAACAGGGTAATC
GATTT-3´ and the reverse primer 5´- 
TGATAATCAATATCTCTGCTATTGTAACCTGGAAGTCTCAGCCAGTGTTACAACCAATTA
ACC-3´. Bold sequences indicate the mutagenesis to stop codons. Sequences in italics 
indicate the I-SceI-aphAI transfer cassette primer binding part. For the generation of the 
SARS-CoV-2 ORF6 chimeric virus, we ordered a synthetic dsDNA construct (IDT), designed 
as a 1349bp transfer cassette for red-recombination with the following build-up: the first 5´ 65 
bp provide the 5´homologous hook to our rSARS-CoV cDNA clone upstream of ORF6 (i.e. the 
last 55 bp of the M gene and the following 10 bp constituting TRS6), followed by the first 141 
bp of SARS-CoV-2 ORF6 sequence (Severe acute respiratory syndrome coronavirus 2 isolate 
Wuhan-Hu-1; accession number MN908947), followed by the the I-SceI-aphAI transfer 
cassette, followed by a 50 bp repeat of the ORF6 sequence (bp 92-142; required for the second 
recombination step) and the last 44 bp of SARS-CoV-2 ORF6, followed by a 65 bp 3´ 
homologous hook to our rSARS-CoV cDNA clone, comprising the sequence immediately 
downstream of ORF6. Electroporation of the transfer constructs, and both recombination steps 
were performed as described in Muth et al., 2017. Bacterial clones carrying the correct insert 
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size after first and second recombination, were identified by PCR using the primers SARS-F-
26918 5` GATCACTGTGGCTACATCACGAAC-3´ and SARS-R-28182 5´ 
GGGTCCACCAAATGTAATGCGG-3´.  
Virus rescue from purified full-length SARS-CoV cDNA clones was performed as described in 
Muth et. 2017 and in chapter 3.28-30. In brief, 5-10 µg extracted cDNA plasmids were 
linearized by 5 µl NotI digestion in 200 µl for 30 minutes. 1 µg of phenol chloroform extracted, 
linearized cDNA was in-vitro transcribed and capped using the mMESSAGE mMACHINE T7 
Transcription Kit (Invitrogen), detailed in chapter 3.28. 1-10 µg in vitro transcripts were 
electroporated into 4x10e6 BHK-J cells (chapter 3.29). 24 hours post electroporation, the 
supernatant was transferred to susceptible Vero E6 cells and virus replication monitored by 
quantitative real-time PCR [237]. Recombinant viruses were harvested three days post 
infection and subjected to virus purification, as described for MERS-CoV.  
3.28 - Linearization and phenol-chloroform extraction of rSARS-CoV 
cDNA 
Prior to in vitro transcription, the 5-10 µg of clones pBelo vectors carrying full SARS cDNA 
genomes were linearized by digestion with 5 µl NotI in 200 µl volume for 1 hour at 37°C. 
Completeness of linearization was confirmed by agarose gel electrophoresis. Linearized 
plasmid was purified by phenol-chloroform and ethanol extraction. In brief, 200 µl 
Phenol/Chloroform/Isoamyl (25:24:1) was added to 200 µl diluted, linearized pBelo vector, 
mixed by inversion and centrifuged for 5 minutes at 11,000x g to allow for phase separation. 
The upper aqueous phase was transferred to a fresh tube and mixed with 200 µl 
Chloroform/Isoamyl (24:1), mixed by inversion and centrifuged for 5 minutes at 11,000x g. The 
upper aqueous phase was transferred to a fresh tube, mixed with 20 µl 3M NaOAc and 400 µl 
ethanol and incubated at -20°C for 30 minutes or overnight. Subsequently, plasmid DNA was 
centrifuged for 30 minutes at 14,000x g, washed and precipitated with 70% ethanol and dried 




3.29 - Generation of infectious rSARS-CoV in vitro transcripts 
In vitro transcription (IVT) and capping of purified, linearized pBelo BAC vectors was done by 
using the mMESSAGE mMACHINE T7 Transcription Kit (Invitrogen) using the following 
reaction. 
2x NTP/CAP 10 µl 
10x T7 Buffer 2 µl 
30mM GTP 2 µl 
T7 enzyme mix 2 µl 
Template (concentration 250 ng/µl) 4 µl 
Total volume: 20 µl 
 
The IVT reaction was incubated at 37°C for 4 hours. Residual input DNA template was digested 
by the addition of 1 µl DNase for 15 minutes. IVT RNA was precipitated by the addition of 30 
µl 7,5M LiCl and 30 µl H2O, followed by a 60 minutes incubation at-20°C, centrifugation at 
14,000x g, 4°C for 30 minutes and subsequent ethanol precipitation. Dried viral RNA 
transcripts were resuspended in 12 µl nuclease free H2O and RNA concentration was 
quantified on a NanoDrop spectrometer (Chapter 3.23). Aliquots of 10 µg were stored at -80°C.  
3.30 - Generation of recombinant virus from in vitro transcripts 
Recombinant viruses are produced by a two-step protocol. 10 µg capped in vitro transcribed 
full genome rSARS-CoV RNA and 2 µg SARS-CoV N transcript were electroporated into a 100 
µl dilution of 4x10e6 BHK-J cells in OptiPro. Pre-cooled 2 mm gaps cuvettes (VWR) were used 
for electroporation. SARS-CoV nucleocapsid transcript is co-electroporated in order to improve 
translation efficiency of viral proteins [238]. The suspension was carefully resuspended on ice 
and electroporated on a Gene Pulser Xcell (Bio-Rad) using a single 140 V pulse for 25 
milliseconds. After electroporation, BHK-J cells were resuspended in 5 ml culture medium and 
transferred to a T25 flask. Hamster kidney derived BHK-J cells can efficiently be electroporated 
and serve as an initial host cell for virus particle production, but hamster cells are not 
susceptible for SARS-CoV infection. For virus stock production, the supernatant of the 
electroporated BHK-J cells was transferred to SARS-CoV susceptible Vero E6 cells 24 hours 
post electroporation. Vero E6 cells were grown to 90% confluency and passaged 1:2 into a 
T162 flask with DMEM culture medium containing 2% FCS, 1 prior to infection. At 0 and 72 hpi 
50 µl supernatant were subjected to isolation of viral RNA (chapter 3.21). Virus replication, as 
a function in increase in viral RNA, was monitored by quantitative real-time PCR (chapter 3.26). 
Upon confirmation of virus replication, the whole culture medium was subjected to virus stock 
production (chapter 3.2).  
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4 – Materials 
 
4.1 - Cell Lines  
Name: Species and tissue: Source: 
293T 
(ATCC-CRL-3216) 
Human fetal liver cell line 
Bernhard Nocht Institute, 
Hamburg 
BHK-J 
(derived from ATCC-CCL-10) 
Baby hamster kidney cell line 



















Human colon cell line 
Steeve Boulant, 
University of Heidelberg 
T84 IFNA/LR KO 
(derived from CCL-248) 
CRISPR knockout of IFN alpha 
and IFN lambda receptor 
Steeve Boulant, 
University of Heidelberg 
Vero (B4 and E6) 
(derived from CCL-248) 
African green monkey 














EMC-2012 2012 A JX869059 
Riyadh_58_2014 2014 B, lineage 3 MN481964 
Riyadh_150_2014 2014 B, lineage 3 MN481965 
Riyadh_146_2014 2014 B, lineage 3 MN481966 
Riyadh_1734_2015 2015 B, lineage 5 MN481979 
Riyadh_1147_2014 2014 B, lineage 3 MN481967 
Riyadh_586_2014 2014 B, lineage 3 MN481968 
Riyadh_1735_2015 2015 B, lineage 5 MN481980 
Riyadh_1737_2015 2015 B, lineage 5 MN481981 
Riyadh_1340_2014 2014 B, lineage 3 MN481969 
Riyadh_1760_2015 2015 B, lineage 5 MN481982 
Riyadh_1758_2015 2015 B, lineage 5 MN481983 
Riyadh_1757_2015 2015 B, lineage 5 MN481984 
Riyadh_1769_2015 2015 B, lineage 5 MN481985 
Jeddah_9042_2014 2014 B, lineage 4 MN481970 
Jeddah_9055_2014 2014 B, lineage 4 MN481971 
Jeddah_9278_2014 2014 B, lineage 4 MN481972 
Jeddah_8965_2014 2014 B, lineage 4 MN481973 
Jeddah_9313_2014 2014 B, lineage 4 MN481974 
Riyadh_1764_2015 2014 B, lineage 5 MN481986 
Jeddah_9289_2014 2014 B, lineage 4 MN481975 
Riyadh_167_2014 2014 B, lineage 3 MN481976 
Jeddah_9355_2014 2014 B, lineage 4 MN481977 
Jeddah_10306_2014 2014 B, lineage 4 MN481978 
 
All virus sequences were uploaded to GenBank and are publically available under the provided 
accession numbers. All viruses were generated from anonymous respiratory swabs of Saudi 




4.3 - SARS- and SARS-CoV-2 isolates 
SARS-CoV-2 strain Munich/2020/984 (BetaCoV/Munich/BavPat1/2020|EPI_ISL_406862) was 
isolated from a respiratory swab obtained from the early 2020 Munich patient cohort [214], 
SARS-CoV-2 strain Victoria (BetaCoV/Australia/VIC01/2020; accession number MT007544). 
SARS-CoV strain Frankfurt (accession number AY310120) was isolated in 2003 from a 
respiratory swab of a SARS patient in Germany 2003 [6]. Recombinant SARS-CoV strain 
Frankfurt (NC_004718), was cloned and rescued by Susanne Pfefferle at the Institute of 
Virology, University of Bonn Medical Center [224]. rSARS-CoV ΔORF6  was cloned by Dr. Doreen 
Muth at the Institute of Virology, University of Bonn Medical Center, in 2016. 
4.4 - Bacteria strains  
Name Source 
E. coli GS1783 Klaus Osterrieder, FU Berlin 
E. coli One Shot Top10 Life Technologies/ made in-house 
E. coli NEB-10 beta NEB 
4.5 - Bacteria medium and supplements  
Name Source 
Carbenicillin (50 µg/ml) Sigma Aldrich-Aldrich 
Kanamycin (30 µg/ml) Sigma Aldrich-Aldrich 
Chloramphenicol (10 µg/ml) Sigma Aldrich-Aldrich 
Lysogeny Broth (LB) broth Carl Roth, Karlsruhe 
Lysogeny Broth (LB) agar Carl Roth, Karlsruhe 
S.O.C Medium NEB 
Stable Outgrow Medium NEB 
4.6 - Enzymes 
Name Application Source 
Antarctic Phosphatase cloning New England Biolabs 
Dpn1 FastDigest cloning Thermo Fisher Scientific 
NotI FastDigest BAC linearization Fermentas 
Phusion High-Fidelity DNA polymerase PCR Thermo Fisher Scientific 
RNAseH PCR Thermo Fisher Scientific 
Superscript III Reverse Transcriptase q-RT-PCR Thermo Fisher Scientific 
TaqPolymerase Colony PCR Thermo Fisher Scientific 
T4 DNA Ligase Cloning Thermo Fisher Scientific 
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4.7 - DNA markers for agarose gel electrophoresis 
Name Source 
1 kb Plus DNA Ladder Invitrogen 
1 kb DNA Ladder Promega 
4.8 - Oligonucleotides (Primers) 
This section contains all primers that were not explicitly mentioned in the methods section. 
Many of these primers were designed by former members of the institute, including Dr. Doreen 
Muth and Dr. Benjamin Meyer. Primer sequences that were obtained from published research 
articles by other research groups are referenced. Primers were either manually designed in 
using the Geneious software, or designed using the primer design tool (Geneious), or using 
the IDT primer design web tool (PrimerQuest Tool). All sequences are provided in the 5´ to 
3´direction.   
4.8.1 - Forward primers for MERS-CoV Sanger sequencing 
Name Sequence 
47 Fwd CAGAACTTTGATTTTAACGAACTTA 
428 Fwd GGATGGCGAAAATGCCTATGAA 
1286 Fwd TGAGTGTGGAAGTTGTGGTAAT 
2640 Fwd GTATCCAGTAACATGGTTGAAACT 
3609 Fwd TTGTCCAATTTTGAACATAAGGTTAT 
4593 Fwd CTCCTGCATTGGTCTGATCAAA 
5669 Fwd GGTATTCTTTGGACGGTAATTTCA 
6092 Fwd CAATAGAGCTAGTTTGCGTCAAAT 
6710 Fwd CGTTGTGACAGGTAATGTTGTAA 
7652 Fwd TTATGTGGATTCCGTTACAGTTAA 
8210 Fwd CAATAATTATGTACCCTCATATGTTAA 
9020 Fwd ATACTGCCATGATCCTACTGTTT 
9827 Fwd AACTAATGATGCCTATTCACGATTT 
10599 Fwd CACCAAGTTCAGTTAACAGACAAA 
11332 Fwd GATTGTACAACCCATCACTTTCTAA 
12558 Fwd GAAATTGTTAAGTCTTCAGATGTTGTA 
13862 Fwd TGCTGTGATGTTACCTACTTTGAA 
15198 Fwd GTGGCTGGGATTTCATGCTTAAA 
16581 Fwd CTACAACAGAACCACTCAAACTT 
17477 Fwd TGTCACTAGATTGATGTGTAACTTA 
18254 Fwd AGCTGGATAGGCTTCGATGTT 
19197 Fwd CACGTGTGCATTCTGAGTTCAAT 
20021 Fwd GGTCCTGATTATGCTTACTTCAAT 
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21015 Fwd ATGTAACAGGTAGTAATGAGTCAAA 
21826 Fwd CCAATTCCACTGGCACTGTTA 
22208 Fwd AGAGTGGTTTGGCATTACACAAA 
22588 Fwd CTGAAGGTGTTGAATGTGATTTT 
23455 Fwd CTAAAACCCACGCTACTCTATT 
24329 Fwd TGGCTGGACTGCTGGCTTAT 
24817 Fwd CACATATAGTGTCCTTTGTTGTAA 
25489 Fwd TCGAGCCGCATAAGGTTCAT 
26767 Fwd GTCTTCCAATCAGGGTAATAAACAA 
28176 Fwd TGGTCATTCAATCCTGAGACTAA 
29503 Fwd AACTTACCCATCAGAACAATGAT 
 
4.8.2 - Reverse primers for MERS-CoV Sanger sequencing  
Name Sequence 
842 Rev CTTAAGCAGATTCTGGGCATATT 
1826 Rev ACCTTTGAGAAGCTGGCGTATT 
2841 Rev GTGCACCTCCCTTAAGTCTAAA 
3278 Rev AGTCTCATGAGAAACGTCAACTT 
3745 Rev ATACCACCGCCATGCTTAAGA 
4074 Rev CTTGGGAATTAACGACGACTAAA 
4719 Rev GTGTCGTGCGTGAATCCAAAT 
5856 Rev CAGACGATACAAGGCAGCTATT 
6839 Rev CAATACCATAGTTGTGCATAACATAA 
8327 Rev ACCATTAGAATTACGCAAGACAATT 
9169 Rev GACAGAGTTCTAGTAATCCTAAGT 
9963 Rev CAGTCTCGCTGTATGTTTGTAA 
10707 Rev CACTAGTGCGATTAGGTTTTACAA 
11489 Rev AGTAACAAAGACTGTAATCGTATAA 
12261 Rev CCTGATCAGCCATACGTTCTAA 
13595 Rev CATCTAATTCTACAAACCTACAAGTAT 
14837 Rev CAACTTCCATGCAGAACAACATT 
15780 Rev TTCTGATAATACAGCGTTTCCTTAA 
16821 Rev TACTCACCGAGCTGCACTTT 
17662 Rev GCTAGCATCATGCGTCACATT 
18375 Rev ACAACACCAACTGGCTGAACAA 
19351 Rev CACTTCACATGGTGTAGTAGAATA 
20138 Rev ACTCAGTAGGATCAATAAACTCATT 
21550 Rev TCAATACAAGCAGACTTAACAGAAT 
22360 Rev GAACGAATACTGTGAGGAATGATA 
23196 Rev GTCTGTACCATATTGAACTGTAAT 
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24057 Rev CACCTCCAAAACCTGGTATGATA 
24917 Rev ACCATAAGCAGAAACAACCTCAAT 
25679 Rev CAGCTTGGGCAGTTTTAATACAA 
26480 Rev AGGCGAACTCATGTAGCTCAAAT 
27587 Rev GACATTATGAAGGAGTTCGTTAAA 
28679 Rev CAGTGTACCAAGAGACAGTGTTA 
29142 Rev CTGATCTTGAACCTTGTGAACTA 
29621 Rev CTCAAGAAGCTCCAACCACTTA 
 
4.8.3 - MERS-CoV Spike mutagenesis primer  
Name Mutation Direction Sequence 










MERS S QS 
Q833R Fwd 
Q833R Forward TTCCAAAATAAACCGGGCTCTCCATGGTGC 
MERS S QS 
Q833R Rev 
Q833R Reverse CAAAACTGGCCATACTCGCGCAGTAATTGC 
MERS S QS 
Q1020R Fwd 
Q1020R Forward TAATGAAGCTTTTCGGAAGGTTCAGGATGC 
MERS S QS 
Q1020R Rev 
Q1020R Reverse GTTGTAGTGAAGCCTGTTTGCATAGCTCCC 
 
4.8.4 - Quantitative real-time PCR primers and probes 
Name Direction Sequence 
TBP  fwd Forward CTGCGGTAATCATGAGGATAAG 
TBP prb Probe TGTGCACAGGAGCCAAGAGTGAAG 
TBP rev Reverse TTCTTGCTGCCAGTCTGGAC 
IFNb1 fwd Forward AGGATTCTGGATTACCTGAAGG 
IFNb1 prb Probe TCCACTCTGACTATGGTCCAGGCA 
IFNb1 rev Reverse GGCTAGGAGATCTTCAGTTTCG 
IFNL1 fwd Forward CTCTGTCACCTTCAACCTCTTC 
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IFNL1 prb Probe CACGCGAGACCTGAATTGTGTTGC 
IFNL1 rev Reverse ATCTCAGGTTGCATGACTGG 
CCL5 fwd Forward TGCCCACATCAAGGAGTATTTC 
CCL5 prb Probe TCACCCGAAAGAACCGCCAAGT 
CCL5 rev Reverse CCATCCTAGCTCATCTCCAAAG 
Mx1 fwd Forward TTCAGCACCTGATGGCCTATC 
Mx1 prb Probe CAGGAGGCCAGCAAGCGCCATC 
Mx1 rev Reverse TGG ATG ATC AAA GGG ATG TGG 
ISG56 fwd Forward CCTGGAGTACTATGAGCGGGC 
ISG56 prb Probe ACAGAGTTCTCAAAGTCAGCAGCCAGTCTCAGT 
ISG56 rev Reverse TGGGTGCCTAAGGACCTTGTC 
TNFa fwd Forward TGGCCCAGGCAGTCAGA 
TNFa prb Probe CATCTTCTCGAACCCCGAGTGACAAGC 
TNFa rev Reverse TGTAGCCCATGTTGTAGCAAACC 
sgN RNA fwd [239] Forward CTCGTTCTCTTGCAGAACTTTG 
sgN RNA prb [239] Probe CACGAGCTGCACCAAATAACACTGTCTC 
sgN RNA rev [239] Reverse GTAAGAGGGACTTTCCCGTGTTG 
MERS ORF1a fwd [190] Forward CCACTACTCCCATTTCGTCAG 
MERS ORF1a prb [190] Probe CAGTATGTGTAGTGCGCATATAAGCA 
MERS ORF1a rev [190] Reverse TTGCAAATTGGCTTGCCCCCACT 
E_Sarbeco_F [237] Forward ACAGGTACGTTAATAGTTAATAGCGT 
E_Sarbeco_P1 [237] Probe ACACTAGCCATCCTTACTGCGCTTCG 




4.9 - Plasmids 
Name Source Application 
pCG1 (empty) M. Hoffman; DPZ Göttingen VSVpp 
pCG1-VSV-G M. Hoffman; DPZ Göttingen VSVpp 
pCG1-MERS-S Cloned by B. Meyer VSVpp 
pCG1-MERS-S-Q1020R This thesis VSVpp 
pCG1-MERS-S-Q1020R-L411F This thesis VSVpp 
pCG1-MERS-S-Q1020R-Q833R This thesis VSVpp 
pBelo-rSARS-wt Cloned by S. Pfefferle [224] rSARS-CoV cloning 
pBelo-rSARS-ORF6-SARS-2 This thesis rSARS-CoV cloning 
pBelo-rSARS-delORF6 Cloned D. Muth and A. Siemens rSARS-CoV cloning 
 
4.10 - Commercial Kits  
Name Application Source 
Nextera® XT DNA Library 
Prep 
Library preparation for NGS Illumina 
MagNA Pure 96 DNA and Viral 




MiSeq Reagent Kit v3 NGS Illumina 
mMessage mMachine T7  In vitro RNA transcription 
Thermo Fisher 
Scientific 
NE-PER Nucleus cytosol fractionation 
Thermo Fisher 
Scientific 
NucleoBond Xtra Midi EF DNA extraction Macherey&Nagel 
NucleoSpin Gel and PCR 
clean-up 
PCR clean-up, gel extraction Macherey&Nagel 
Renilla Luciferase Assay 
System 
VSVpp quantification Promega 









4.11 - Antibodies 
Antibody Source Application* 
Anti VSV-G, from CRL-2700 ATCC VSVpp 
AlexaFlour488-conjugated anti-human  Thermo Fisher Scientific VSVpp 
Soluble DPP4 C-terminal human Fc-tag ACROBiosystems VSVpp 
p-IRF3 cs#4947s Cell Signaling Technology Western blot 
IRF3 cs#4302s Cell Signaling Technology Western blot 
IκBα cs#4812s Cell Signaling Technology Western blot 
SARS-CoV-N GTX632269 Genetex Western blot 
ß-Actin A5316 Sigma Aldrich Western blot 
NFkB p65 cs#6956s Cell Signaling Technology Western blot 
STAT-1 cs#9172 Cell Signaling Technology Western blot 
GAPDH cs#5174s Cell Signaling Technology Western blot 
Histone H3 H0164 Sigma Aldrich Western blot 
Goat anti-Rabbit IgG, HRP, 65-6120 Thermo Scientific Western blot 
Goat anti-Mouse IgG, HRP, 62-6520 Thermo Scientific Western blot 
*Applied dilutions are provided in chapter 3.17-20 
4.12 - Software 
Name: Application Source 











Display and editing of 
phylogenetic trees 












(RaxML and MrBayes); 
NGS read assembly 
and editing; Sanger 






Plotting of all data; 

















Open access; [240] 
http://www.cbs.dtu.dk/services/NetOGlyc/ and 
[241] http://www.cbs.dtu.dk/services/NetNGlyc/  
SimPlot 
3.5.1 
Bootstrap analysis for 
recombination 
detection 
[242], open access https://omictools.com/simplot-
tool 
4.13 - Technical Equipment 
Equipment Model Source 
Autoclave S2 VS-100 Systec 
Autoclave S3 Custom made Matachana 
BSL3 respirator OptimAir 3000 MSA 
Blotting system TransBlotTurbo BioRad 
Balance Kern 572 Kern 
Centrifuge Eppendorf 5424 Eppendorf 
Centrifuge Eppendorf 5430R Eppendorf 
Centrifuge Eppendorf 5810R Eppendorf 
Electroporation System Gene Pulser Xcell Bio-Rad 
Freezer -20er Liebherr 
Freezer -80er, Model U725 New Brunswick 
Gel electrophoresis System 41-1325 Peqlab 
Gel documentation Universal Hood II Bio-Rad 
Heating block TS pro CellMedia 
Hood (Sterile bench) Safe2020 Thermo Fisher Scientific 
Incubator C170 Binder 
Microscope cell culture CK30 Olympus 
Microscope BSL3 Axio Oberserver Zeiss 
Microscope (confocal) LSM800 Airyscan Zeiss 
Multistep Pipette HandyStep Brand 
Multichannel Pipette Xplorer Eppendorf 
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NGS sequencing platform MiSeq System Illumina 
PCR cycler Nexus Gradient Eppendorf 
Photometer Nanodrop 1000 Thermo Fisher Scientific 
Pipettes 
Research Plus, 100-1000 µl, 
10-100 µl, 0.5-10 µl, 0.1-2 µl 
Eppendorf 
Power supply Standard Power Pack P25 Biometra 
Real-time PCR Cycler LightCycler 480 II Roche Diagnostics 





5 - Abbreviations 
Abbreviation Full name 
3CLpro chymotrypsin-like protease 3 
ACE2 Angiotensin-converting enzyme 2 




CPE Cytoplasmic effect 
CT Cycle treshold 
CTD C-terminal domain 
DPP4 Dipeptidylpeptidase 4 
DMEM Dulbecco's Modified Eagle's Medium 
dsRNA Double-stranded RNA 
E Envelope protein 
EndoU uridylate-specific endoribonuclease 
ExoN Exonuclease  
GTR  general time reversible 
HAE Human airway epithelium 
hpi hours post infection 
IFIT Interferon-induced protein with tetratricopeptide repeats 
IFITM Interferon-induced transmembrane proteins 
IFN Interferon 
ISG Interferon stimulated gene 
ISRE Interferon stimulated response element 
IVT in vitro transcription 
JAK Januskinase 
KO Knock out 
kbp kilobasepairs 
LB Lysogeny broth 
M Membrane protein 
MAVS Mitochondrial antiviral-signaling protein 
MERS Middle East respiratory syndrome 
MOI Multiplicity of infection 
N Nucleocapsid protein 
NF-kB nuclear factor 'kappa-light-chain-enhancer' of activated B-cells 
nsp Non-structural protein 
NTD N-terminal domain 
ORF Open reading frame 




PBS Phosphate buffered saline 
pp polyprotein 
PACT Protein activator of the interferon-induced protein kinase 
PAMP Pathogen associated molecular patter 
PCR Polymerase chain reaction 
PFU Plaque forming unit 
PLpro Papain-like protease  
PRNT Plaque reduction neutralization test 
PRR Pattern recognition receptor 
q-RT-PCR Quantitative real-time PCR 
RBD Receptor-binding domain 
RdRp RNA dependent RNA polymerase 
rSARS-CoV Recombinant SARS-CoV 
S Spike protein 
SARS Severe acute respiratory syndrome 
sg subgenomic 
sgmRNA Subgenomic messenger RNA 
TMPRSS2 transmembrane protease serine subtype 2 
TRS Transcription regulatory sequence 




6 - Supplements 
 
Supplementary Figure 1: Overview of SNPs in coding regions of MERS-CoV isolates 
generated in this thesis (relative to the reference strain EMC). Green arrows indicate the 
gene in which the SNP is located. Each black dash indicates a SNP in comparison to the 
reference strain (EMC). SNPs that encode for amino acid exchanges between the MERS-CoV 
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Supplementary Table 1: Amino acid divergence of generated MERS-CoV isolates reflecting 
changes found in all isolates of the respective phylogenetic lineage. AA = amino acid; the AA 
positions for nsp1-15 are provided relative to the start of ORF1ab. An overview of amino acid 
divergence in the spike protein is provided in supplementary figure 2.  
 
nsp1 
AA position 8 158 
lineage 3 I F 
lineage 4 T F 
lineage 5 I V 
 
 nsp2 
AA position 219 519 
lineage 3 E L 
lineage 4 K L 
lineage 5 K I 
  
 nsp3 
AA position 1000 1040 1045 1072 1110 1236 
lineage 3 V A A Q L A 
lineage 4 I A A Q P A 
lineage 5 V V V R P T 
  
 nsp3 
AA position 1700 1794 1835 1964 2003 2119 2215 2426 
lineage 3 C P E A A M K T 
lineage 4 R S E E A M K T 
lineage 5 R P A A V I E I 
 
 nsp4 
AA position 2747 
lineage 3 A 
lineage 4 A 




AA position 3785 
lineage 3 L 
lineage 4 F 




AA position 3947 
lineage 3 Q 
lineage 4 Q 






Supplementary Table 1 (continued): 
 nsp10 
AA position 4373 
lineage 3 A 
lineage 4 A 




AA position 5574 
lineage 3 N 
lineage 4 S 
lineage 5 S 
 
 nsp14 
AA position 5957 6368 6381 
lineage 3 V I T 
lineage 4 V I A 
lineage 5 I V A 
 
 nsp15 
AA position 6580 
lineage 3 M 
lineage 4 M 
lineage 5 I 
 
 protein 3 
AA position 17 85 
lineage 3 L G 
lineage 4 L G 




AA position 6 47 85 
lineage 3 M F F 
lineage 4 M L L 
lineage 5 T L L 
  
 M 
AA position 123 
lineage 3 F 
lineage 4 F 




AA position 11 126 144 283 
lineage 3 S D L L 
lineage 4 S H S L 
lineage 5 F D S F 
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Supplementary Table 2: Summary of MERS-CoV isolates that were used in each experiment 
and their respective phylogenetic lineage (accession numbers are provided in chapter 4.2). 
 
Figure MERS-CoV isolate lineage 
8A Riyadh-146 2014 3  
Riyadh-1147 2014 3  
Jeddah-9278 2014 4  
Jeddah-10306 2014 4  
Riyadh-1734 2015 5  
Riyadh-1764 2015 5   
 
8B Riyadh-58 2014 3  
Riyadh-146 2014 3  
Riyadh-150 2014 5  
Riyadh-167 2014 5  
Riyadh-586 2014 3  
Riyadh-1147 2014 3  
Riyadh-1340 2014 3  
Jeddah-8965 2014 4  
Jeddah-9042 2014 4  
Jeddah-9055 2014 4  
Jeddah-9278 2014 4  
Jeddah-9313 2014 4  
Jeddah-9355 2014 4  
Jeddah-9355 2014 4  
Jeddah-10306 2014 4  
Riyadh-1734 2015 5  
Riyadh-1735 2015 5  
Riyadh-1737 2015 5  
Riyadh-1757 2015 5  
Riyadh-1758 2015 5  
Riyadh-1760 2015 5  
Riyadh-1764 2015 5  
Riyadh-1769 2015 5 
   
8C Riyadh-146 2014 3 
 Riyadh-1147 2014 3 
 Jeddah-9278 2014 4 
 Jeddah-10306 2014 4 
 Riyadh-1734 2015 5 
 Riyadh-1764 2015 5 
   
8D Riyadh-1147 2014 3 
 Jeddah-10306 2014 4 





Supplementary Table 2 (continued): 
 
Figure MERS-CoV isolate Lineage 
9 Riyadh-1147 2014 3  
Riyadh-1764 2015 5  
  
   
10 VSVpp 3 
 VSVpp 4 
 VSVpp 5 
   
11 Riyadh-1147 2014 3 
 Jeddah-10306 2014 4 
 Riyadh-1764 2015 5 
   
12 Riyadh-1147 2014 3 
 Jeddah-10306 2014 4 
 Riyadh-1734 2015 5 
   
13 Riyadh-146 2014 3 
 Riyadh-1147 2014 3 
 Jeddah-9289 2014 4 
 Jeddah-10306 2014 4 
 Riyadh-1734 2015 5 
 Riyadh-1737 2015 5 
   
14 Riyadh-146 2014 3 
 Riyadh-167 2014 3 
 Jeddah-9278 2014 4 
 Jeddah-9289 2014 4 
 Riyadh-1734 2015 5 
 Riyadh-1737 2015 5 
   
15 Riyadh-1147 2014 3 
 Riyadh-146 2014 3 
 Jeddah-8965 2014 4 
 Jeddah-9278 2014 4 
 Riyadh-1764 2015 5 
 Riyadh-1734 2015 5 
   
16A Riyadh-1147 2014 3 
 Riyadh-146 2014 3 
 Jeddah-10306 2014 4 
 Jeddah-9278 2014 4 
 Riyadh-1764 2015 5 
 Riyadh-1734 2015 5 
   
16B Riyadh-1147 2014 3 
 Jeddah-10306 2014 4 




Supplementary Figure 2: Differences in the spike protein amino acid sequence of the MERS-
CoV isolates investigated in this study. The EMC reference spike protein sequence was used 
as a reference for the alignment. Numbers indicate the respective amino acid position. S1/2 = 
subunit 1/2; SP = signal peptide; NTD = N-terminal domain; RBD = receptor-binding domain; 




strain 411 833 1020
EMC L Q Q
lineage 3 Riyadh-58 2014 F ∙ R
lineage 3 Riyadh-146 2014 F ∙ R
lineage 3 Riyadh-150 2014 F ∙ R
lineage 3 Riyadh-167 2014 F ∙ R
lineage 3 Riyadh-586 2014 F ∙ R
lineage 3 Riyadh-1147 2014 F ∙ R
lineage 3 Riyadh-1340 2014 F ∙ R
lineage 5 Riyadh-1734 2015 ∙ ∙ R
lineage 5 Riyadh-1735 2015 ∙ ∙ R
lineage 5 Riyadh-1737 2015 ∙ ∙ R
lineage 5 Riyadh-1757 2015 ∙ ∙ R
lineage 5 Riyadh-1758 2015 ∙ ∙ R
lineage 5 Riyadh-1760 2015 ∙ ∙ R
lineage 5 Riyadh-1764 2015 ∙ ∙ R
lineage 5 Riyadh-1769 2015 ∙ ∙ R
lineage 4 Jeddah-8965 2014 ∙ R R
lineage 4 Jeddah-9042 2014 ∙ R R
lineage 4 Jeddah-9055 2014 ∙ R R
lineage 4 Jeddah-9278 2014 ∙ R R
lineage 4 Jeddah-9289 2014 ∙ R R
lineage 4 Jeddah-9313 2014 ∙ R R
lineage 4 Jeddah-9355 2014 ∙ R R




Supplementary Figure 3: CPE induction by SARS- and SARS-CoV-2 in Calu-3 and Vero E6 
cells, with IFN treatment as indicated. Images were taken on a Zeiss Axio Observer with 20x 
magnification   




Vero E6 IFN-β pretreatment (SARS-CoV-2 moi = 0.001)
Calu-3 IFN-β posttreatment (SARS-CoV-2 moi = 0.001) 
D Vero E6 IFN-β posttreatment (SARS-CoV-2 moi = 0.001) 
2,000
IFN-β[IU/ml]0 100 400 1,000
IFN-β[IU/ml]0 1,000 2,000 4,000
IFN-β[IU/ml]0 100 400 1,000
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